<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Beclometasone for chronic obstructive pulmonary disease - De Coster, DA - 2013 | Cochrane Library</title> <meta content="Beclometasone for chronic obstructive pulmonary disease - De Coster, DA - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009769.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Beclometasone for chronic obstructive pulmonary disease - De Coster, DA - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009769.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009769.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Beclometasone for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Daan A De Coster" name="citation_author"/> <meta content="University College London, Upper 3rd Floor, UCL Medical School (Royal Free Campus)" name="citation_author_institution"/> <meta content="d.coster@ucl.ac.uk" name="citation_author_email"/> <meta content="Melvyn Jones" name="citation_author"/> <meta content="UCL" name="citation_author_institution"/> <meta content="Nikita Thakrar" name="citation_author"/> <meta content="UCL" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD009769.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/10/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009769.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009769.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009769.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐2 Receptor Agonists [*therapeutic use]; Beclomethasone [*therapeutic use]; Forced Expiratory Volume [drug effects, physiology]; Glucocorticoids [*therapeutic use]; Pulmonary Disease, Chronic Obstructive [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009769.pub2&amp;doi=10.1002/14651858.CD009769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009769\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009769\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009769.pub2",title:"Beclometasone for chronic obstructive pulmonary disease",firstPublishedDate:"Oct 9, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009769.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009769.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009769.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009769.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009769.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009769.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009769.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009769.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009769.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009769.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3256 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009769.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-sec-0119"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-sec-0104"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/appendices#CD009769-sec-0124"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/table_n/CD009769StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/table_n/CD009769StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Beclometasone for chronic obstructive pulmonary disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/information#CD009769-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Daan A De Coster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/information#CD009769-cr-0003">Melvyn Jones</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009769.pub2/information#CD009769-cr-0004">Nikita Thakrar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/information/en#CD009769-sec-0134">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 October 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009769.pub2">https://doi.org/10.1002/14651858.CD009769.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009769-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009769-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009769-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009769-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009769-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009769-abs-0001" lang="en"> <section id="CD009769-sec-0001"> <h3 class="title" id="CD009769-sec-0001">Background</h3> <p>Chronic obstructive pulmonary disease (COPD) is a chronic obstructive lung condition, diagnosed in patients with dyspnoea, chronic cough or sputum production and/or a history of risk factor exposure, if their postbronchodilator forced expiratory lung volume in 1 second (FEV<sub>1</sub>)/forced vital lung capacity (FVC) ratio is less than 0.70, according to the international GOLD (Global Initiative for Obstructive Lung Disease) criteria. </p> <p>Inhaled corticosteroid (ICS) medications are now recommended for COPD only in combination treatment with long‐acting beta<sub>2</sub>‐agonists (LABAs), and only for patients of GOLD stage 3 and stage 4 severity, for both GOLD groups C and D. </p> <p>ICS are expensive and how effective they are is a topic of controversy, particularly in relation to their adverse effects (pneumonia), which may be linked to more potent ICS. It is unclear whether beclometasone dipropionate (BDP), an unlicensed but widely used inhaled steroid, is a safe and effective alternative to other ICS. </p> </section> <section id="CD009769-sec-0002"> <h3 class="title" id="CD009769-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety in COPD of inhaled beclometasone alone compared with placebo, and of inhaled beclometasone in combination with LABAs compared with LABAs alone. </p> </section> <section id="CD009769-sec-0003"> <h3 class="title" id="CD009769-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register of trials (CAGR) (includes Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts) (February 2013), conference abstracts, ongoing studies and reference lists of articles. We contacted pharmaceutical companies and drug marketing authorisation bodies/ethics committees in 49 countries and obtained licensing information. </p> </section> <section id="CD009769-sec-0004"> <h3 class="title" id="CD009769-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of BDP compared with placebo, or BDP/LABA compared with LABA, in stable COPD. Minimum trial duration is 12 weeks. </p> </section> <section id="CD009769-sec-0005"> <h3 class="title" id="CD009769-sec-0005">Data collection and analysis</h3> <p>Inclusion, bias assessment and data extraction were conducted by two review authors independently. The analysis was performed by one review author. Study authors were contacted to obtain missing information. </p> </section> <section id="CD009769-sec-0006"> <h3 class="title" id="CD009769-sec-0006">Main results</h3> <p>For BDP versus placebo, two studies were included, of which one trial (participants n = 194) was included in the quantitative analysis. This study was a very high‐dose trial with stable stage 2 and 3 COPD participants. No statistically significant results in change in lung function, mortality, exacerbations, dyspnoea scores or withdrawal were obtained. The quality of the evidence of all these outcomes was graded low to very low. Data on risk of pneumonia were lacking. </p> <p>The main focus of the review was the more clinically relevant BDP/LABA versus LABA arm. Therefore the findings are reported more fully. </p> <p>For BDP/LABA versus LABA, one study (n = 474) was included, with a further ongoing study identified for future inclusion. The included trial was a high‐dose study of stable stage 3 COPD participants. Compared with LABA, people receiving BDP/LABA showed a statistically significant improvement in FEV<sub>1</sub> lung function measurements of 0.051 L (95% confidence Interval (CI) 0.001 to 0.102, P = 0.046) (high quality of evidence) and in (self‐reported) days without rescue bronchodilators (mean difference 7.05, 95% CI 0.84 to 13.26, P = 0.03) (low quality), both of which are unlikely to be clinically significant. Participants receiving BDP/LABA also had a statistically significant increased rate of exacerbations leading to hospitalisation (risk ratio (RR) 1.84, 95% CI 1.17 to 2.90, P = 0.008) (moderate quality), although this finding is debatable as this study's post hoc analysis showed no statistically significant difference when accounting for country‐specific differences in hospitalisation policies. We did not find statistically significant differences for mortality (very low quality), pneumonia (low quality), exacerbations, exercise capacity, quality of life and dyspnoea scores, adverse events and withdrawal (all moderate quality). </p> </section> <section id="CD009769-sec-0007"> <h3 class="title" id="CD009769-sec-0007">Authors' conclusions</h3> <p>We found little evidence to suggest that beclometasone is a safer or more effective treatment option for people with COPD when compared with placebo or when used in combination with LABA; when statistically significant differences were found, they mostly were not clinically meaningful or were based on data from only one study. The review was limited by an inability to obtain data from one study and likely publication bias for BDP versus placebo, and by the inclusion of one study only for BDP/LABA versus LABA. An ongoing study of BDP/LABA versus LABA may have a further impact on these conclusions. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009769-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009769-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009769-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009769-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009769-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009769-abs-0004" lang="en"> <h3>The effect of steroid inhalers containing the drug beclometasone for patients with COPD </h3> <p><b>Background</b> </p> <p>Chronic obstructive pulmonary disease (COPD; i.e. chronic bronchitis or emphysema or both, also called "smoker's lung disease") is a disease in which patients (predominantly smokers) experience breathlessness and produce a lot of phlegm or sputum. COPD is diagnosed by using international guidelines provided by the Global Initiative for Obstructive Lung Disease (GOLD). </p> <p>One of the treatments that may be used to slow down worsening of this disease consists of steroid inhalers. These inhalers are known as preventer inhalers because they are taken daily to prevent symptoms. GOLD recommends that steroid inhalers are now to be used only in combination with inhaled LABA drugs (long‐acting beta<sub>2</sub>‐agonists, e.g. formoterol). They are recommended for patients who have COPD with high risk of flare‐ups ("exacerbations"). </p> <p><b>Why do this review?</b> </p> <p>It is still unsure whether these steroid preventer inhalers, such as beclometasone inhalers, make a difference to patients with COPD. </p> <p>Therefore we decided to do a systematic review of existing studies to look into the effects and side effects of beclometasone inhalers for people with COPD. </p> <p><b>Which questions does this review try to answer?</b> </p> <p>Our study consisted of two parts: (A) Are beclometasone inhalers better than placebo? and (B) Is beclometasone in combination with LABA drugs in one inhaler (a beclometasone/formoterol combination inhaler) better than a LABA (formoterol) inhaler? </p> <p><b>How did this review do this?</b> </p> <p>We searched all research papers of clinical trials on this topic and made a special effort to find unpublished trials. </p> <p>We compared effects on breathing ability, death rates, how often pneumonias and flare‐ups happened, how often rescue inhalers had to be used, quality of life and side effects. </p> <p>The evidence obtained is up to date to February 2013.</p> <p><b>What were the results?</b> </p> <p>For (A) we found two studies, with a total of 298 study participants. For (B) we found one study, with 474 study participants, all with severe (stage 3) COPD. </p> <p>For (A) we found no differences that could not be due to chance (not "statistically significant"). Therefore we found no evidence that beclometasone is better or worse than placebo for COPD. It is possible that this conclusion is not fully informed, however, as we were able to use only one trial. We await further statistics from another trial, and we suspect that many trials addressing (A) have gone unpublished in the past. </p> <p>For (B) we found real differences in breathing capacity and rescue inhalers ("statistically significant"), but as the differences were small, they are unlikely to be noticeable for patients (not "clinically significant"). We also found a real increase in the average rate of severe flare‐ups of COPD requiring hospital admission when study participants were using steroid‐containing inhalers. However, the trial authors showed that these differences could have been caused by different hospital policies in the many countries that participated. For the other aspects that we compared, we found no differences in benefits or harms; any differences found were so small that they could have been due to chance. Further research is being done in this area, and findings of these studies may change our conclusions in the future. </p> <p><b>Are there any criticisms of this review's results?</b> </p> <p>Our conclusions are limited by the small number of studies that were useful (only three), the poor/average quality of the evidence and the fact that most of these studies apply only to patients with severe but very stable COPD. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009769-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009769-sec-0119"></div> <h3 class="title" id="CD009769-sec-0120">Implications for practice</h3> <section id="CD009769-sec-0120"> <p>As current practice is to use BDP/LABA for stage 3 COPD, we will focus on this arm of the study to draw conclusions. </p> <p>Upon balancing the benefits and harms, no clear evidence was found to support the benefit of using BDP/LABA inhalers over LABA alone. Three outcomes reached 95% statistical significance (lung function, mean rate of exacerbations leading to hospitalisation and rescue bronchodilator frequency). This increased rate of severe exacerbations is open to interpretation, whereas lung function and rescue inhaler usage effect sizes are small and are unlikely to be clinically significant. </p> <p>The quality of evidence of our primary outcomes ranged from high (lung function) to low and very low (pneumonia and mortality, respectively), but the other outcomes (including exacerbations) were mainly of moderate quality. </p> <p>Although most patients will not experience any benefit of taking BDP/LABA compared with LABA, any given individual may do. The mean effect is the average of an unknown distribution and does not rule out the possibility of some individuals obtaining clinically important benefits. </p> <p>The values and preferences of the patient should be taken into account when decision is made whether to prescribe these inhalers. It is worth reminding that BDP and BDP/LABA are currently unlicensed for use in COPD in many countries, so clinicians should exercise care in their use and should discuss this with their patients. </p> <p>We did not conduct a cost‐effectiveness analysis, so we cannot comment on implications for resource allocations. However, although BDP is cheaper than other ICS drugs, clinicians should be mindful of the lack of effectiveness data on hospitalisation—the primary cost driver with this disease. </p> </section> <h3 class="title" id="CD009769-sec-0121">Implications for research</h3> <section id="CD009769-sec-0121"> <p>We await the publication of another trial comparing BDP/LABA with LABA (<a href="./references#CD009769-bbs2-0017" title="SinghD , KampschulteJ ,  WedzichaJA ,  JonesPW ,  CohuetG ,  CorradiM ,  etal . A trial of beclomethasone/formoterol in COPD using EXACT‐PRO to measure exacerbations. European Respiratory Journal2013;41(1):12‐7. [DOI: 10.1183/09031936.00207611; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/22653766] WedzichaWA . BDP/FF versus formoterol fumarate (FF) in patients with severe COPD (lung function and exacerbation rate). http://clinicaltrials.gov/ct2/show/NCT00929851 (accessed 26 June 2013). ">Wedzicha (FORWARD) 2013</a>), which is likely to be included. This may increase our confidence in some of the results. </p> <p>The research included in this review was conducted in participants with stage 3 COPD. More research is needed to look at the effectiveness of BDP/LABA in different stages of COPD. </p> <p>An adequately powered head‐to‐head study of BDP versus the more potent ICS in combination with LABAs using important outcomes for participants such as hospitalisation might identify substantial cost savings for health services. </p> <p>To address the long‐term benefits and harms of BDP/LABA (mortality, adverse events), research with higher power and with a longer follow‐up period is needed. This may be more feasible with the use of observational cohort studies. </p> <p>Last, we hope this review will stimulate future reviews that will look separately at the other ICS in COPD, so that these can be compared in an overview. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009769-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009769-sec-0022"></div> <div class="table" id="CD009769-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beclometasone/LABA compared with LABA for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beclometasone/LABA compared with LABA for COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20<br/> <b>Settings:</b> 76 centres in 8 European countries (Bulgaria, France, Italy, Poland, Russia, Spain, Ukraine, United Kingdom)<br/> <b>Intervention:</b> beclometasone/formoterol<br/> <b>Comparison:</b> formoterol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Formoterol</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Beclometasone/Formoterol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in FEV<sub>1</sub> </b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in FEV<sub>1</sub> in the intervention groups was<br/> <b>0.05 higher</b> <br/> (0 to 0.1 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality (all‐cause) (dichotomous Peto method)</b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 7.48</b> <br/> (0.47 to 120) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>474<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia: participants with at least one (dichotomous Peto odds ratios)</b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> <br/> (3 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 3.88</b> <br/> (0.78 to 19.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>474<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations: participants with at least one (dichotomous)</b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>283 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 1000</b> <br/> (202 to 364) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.96</b> <br/> (0.64 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life: SGRQ</b> <br/> Scale: 0 to 100<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in quality of life: SGRQ in the intervention groups was<br/> <b>0.85 lower</b> <br/> (3.32 lower to 1.62 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: candidiasis</b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>474<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal (all‐cause)</b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (83 to 203) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.91</b> <br/> (0.54 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>474<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Indirectness of outcome. Unlikely to have been powered for this outcome. May be more appropriate to measure this outcome with e.g. a cohort study.<br/> <sup>2</sup>Wide confidence intervals.<br/> <sup>3</sup>Few events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009769-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Beclometasone compared with placebo for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beclometasone compared with placebo for COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with stable stage 2 and 3 COPD (mainly FEV<sub>1</sub> 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers<br/> <b>Settings:</b> outpatient lung clinics in France (and additionally, for "withdrawals", the UK)<br/> <b>Intervention:</b> beclometasone<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Beclometasone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in FEV<sub>1</sub> </b> —<b>at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in FEV<sub>1</sub>—at 2 years in the intervention groups was<br/> <b>0.03 higher</b> <br/> (0.25 lower to 0.31 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality (all‐cause) (dichotomous Peto method)</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (14 to 157) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.94</b> <br/> (0.26 to 3.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia: participants with at least one (dichotomous Peto odds ratios)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations: participants with at least one (dichotomous)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptoms: change in dyspnoea scale (Fletcher Scale)</b> <br/> Fletcher dyspnoea scale (1 to 5)<br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean symptoms: Change in dyspnoea scale (Fletcher Scale) in the intervention groups was<br/> <b>0.05 higher</b> <br/> (0.06 lower to 0.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: candidiasis</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> <br/> (5 to 151) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.41</b> <br/> (0.24 to 8.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal (all‐cause)</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>336 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>402 per 1000</b> <br/> (295 to 520) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.33</b> <br/> (0.83 to 2.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The Derenne 1995 study was assessed as at high risk of incomplete outcome data for FEV<sub>1</sub> (see the <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> 'Risk of bias' table).<br/> <sup>2</sup>Wide confidence intervals (includes null effect).<br/> <sup>3</sup>For the beclometasone versus placebo studies, we strongly suspected publication bias (see section "Potential biases in the review process").<br/> <sup>4</sup>All‐cause mortality is a very objective outcome measure, and no significant difference was noted in participants lost to follow‐up through withdrawal.<br/> <sup>5</sup>Indirectness of outcome, as the Derenne study was unlikely to be powered for comparing this outcome. A cohort study may be more appropriate. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009769-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009769-sec-0023"></div> <section id="CD009769-sec-0024"> <h3 class="title" id="CD009769-sec-0024">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is a condition with significant mortality and morbidity worldwide. The World Health Organization (WHO) reported that 63.6 million people suffered from the condition in 2004. It was the fourth leading cause of death, accounting for 5.1% of all deaths. Ninety per cent of deaths occurred in low‐income and middle‐income countries. Even so, in high‐income countries, it was still the fifth leading cause of mortality. As it is a chronic condition, it was the thirteenth biggest cause of disease burden worldwide, but it is projected to become the fifth by 2030 (<a href="./references#CD009769-bbs2-0077" title="World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: WHO Press, 2008. ">WHO 2008</a>). </p> <p>According to the international guidelines provided by the Global Initiative for Obstructive Lung Disease (GOLD) and the guidelines of the American Thoracic Society/European Respiratory Society (ATS/ERS), a diagnosis of COPD is made in individuals with dyspnoea, chronic cough or sputum production and/or a history of risk factor exposure if their postbronchodilator forced expiratory lung volume in 1 second (FEV<sub>1</sub>)/forced vital lung capacity (FVC) ratio is less than 0.70 (<a href="./references#CD009769-bbs2-0022" title="American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients With COPD. 1.2. New York: American Thoracic Society, 2004. ">ATS/ERS 2004</a>; <a href="./references#CD009769-bbs2-0038" title="Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.org/. Barcelona: Global Initiative for Chronic Obstructive Lung Disease, Inc., (accessed 12 January 2011). ">GOLD 2010</a>). Both guidelines classify COPD severity, according to postbronchodilator FEV<sub>1</sub>, into stage 1 (mild); stage 2 (moderate); stage 3 (severe); and stage 4 (very severe), respectively, as FEV<sub>1</sub> ≥ 80% predicted; FEV<sub>1</sub> &lt; 80% predicted; FEV<sub>1</sub> &lt; 50% predicted; and FEV<sub>1</sub> &lt; 30% predicted. This classification was subsequently adopted by the UK National Institute for Health and Clinical Excellence (NICE) in 2010 (<a href="./references#CD009769-bbs2-0060" title="National Collaborating Centre for Acute and Chronic Conditions. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care, 2010. http://www.nice.org.uk/guidance/CG101 (accessed 7/10/13). ">NCGC 2010</a>). </p> <p>Although most intervention clinical trials are based around this spirometry‐based staging, FEV<sub>1</sub> alone is insufficient for prediction of disease severity (<a href="./references#CD009769-bbs2-0039" title="Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.org/ (accessed 7 October 2013). ">GOLD 2013</a>). Hence, the <a href="./references#CD009769-bbs2-0039" title="Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.org/ (accessed 7 October 2013). ">GOLD 2013</a> guidance also takes into account individual patients' symptoms (using the COPD Assessment Test (CAT) or the modified British Medical Research Council questionnaire (mMRC)) and future risk of exacerbations (using either FEV<sub>1</sub> staging or the number of exacerbations in the last year, whichever denotes higher risk). Patients corresponding to stage 1 to 2 and/or with 0 to 1 exacerbations per year (low risk) will therefore belong to group A (CAT &lt; 10 or mMRC grade 0 to 1; few symptoms) or group B (CAT ≥ 10 or mMRC ≥ 2; more symptoms). Patients deemed at high risk correspond to stage 3 to 4 and/or have ≥ 2 exacerbations per year, either with few symptoms (CAT &lt; 10 or mMRC grade 0 to 1)—group C—or with more symptoms (CAT ≥ 10 or mMRC ≥ 2)—group D. </p> </section> <section id="CD009769-sec-0025"> <h3 class="title" id="CD009769-sec-0025">Description of the intervention</h3> <p>Beclometasone dipropionate is an inhaled corticosteroid (ICS) used in asthma and COPD. It was first introduced for asthma in 1972 (<a href="./references#CD009769-bbs2-0027" title="BrownHM , StoreyG , GeorgeWH . Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. British Medical Journal1972;1(5800):585‐90. ">Brown 1972</a>). In the UK and in many other countries, it is not licenced specifically for COPD, but because of the historical overlap between asthma and COPD, this practice has seldom been questioned. Other corticosteroids used include budesonide, fluticasone propionate and mometasone furoate. Inhaled corticosteroids are recommended as additional treatment to long‐acting beta<sub>2</sub>‐agonists (LABAs) for stage 3 and 4 COPD patients with repeated exacerbations (<a href="./references#CD009769-bbs2-0022" title="American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients With COPD. 1.2. New York: American Thoracic Society, 2004. ">ATS/ERS 2004</a>; <a href="./references#CD009769-bbs2-0038" title="Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.org/. Barcelona: Global Initiative for Chronic Obstructive Lung Disease, Inc., (accessed 12 January 2011). ">GOLD 2010</a>; <a href="./references#CD009769-bbs2-0060" title="National Collaborating Centre for Acute and Chronic Conditions. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care, 2010. http://www.nice.org.uk/guidance/CG101 (accessed 7/10/13). ">NCGC 2010</a>). New guidance recommends inhaled corticosteroids combined with LABAs (or long‐acting anticholinergics alone instead) for group C patients; and ICS with LABAs and/or long‐acting anticholinergics, among other alternative options, for group D patients (<a href="./references#CD009769-bbs2-0039" title="Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.org/ (accessed 7 October 2013). ">GOLD 2013</a>). </p> <p>Available inhalers that combine ICS and LABA are fluticasone propionate and salmeterol (marketed as <i>Seretide</i> and <i>Advair</i> by GlaxoSmithKline), budesonide and formoterol fumarate (marketed as <i>Symbicort</i> by AstraZeneca), mometasone and formoterol (marketed as <i>Dulera</i> and <i>Zenhale</i> by Merck/MSD) and most recently beclometasone dipropionate and formoterol fumarate (marketed as <i>Fostair</i> and <i>Foster</i> by Chiesi). </p> </section> <section id="CD009769-sec-0026"> <h3 class="title" id="CD009769-sec-0026">How the intervention might work</h3> <p>Inhaled corticosteroids are thought to reduce local inflammation in the bronchial tree, thereby alleviating airflow obstruction. Beclometasone dipropionate itself is "a pro‐drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone‐17‐monopropionate (B‐17‐MP), which has potent topical anti‐inflammatory activity" (<a href="./references#CD009769-bbs2-0055" title="Medicines and Healthcare products Regulatory Agency (MHRA). CLENIL® MODULITE® 50 micrograms peractuation pressurised inhalation solution (beclometasone dipropionate) PL 08829/0133 Public Assessment Report. www.mhra.gov.uk/home/groups/l‐unit1/documents/.../con014210.pdf‎ (accessed 26 June 2013). ">MHRA 2006</a>). </p> </section> <section id="CD009769-sec-0027"> <h3 class="title" id="CD009769-sec-0027">Why it is important to do this review</h3> <p>COPD places a high financial burden on healthcare budgets. In the UK, the annual per patient cost was estimated at GBP1639 in 2003 (<a href="./references#CD009769-bbs2-0024" title="BrittonM . The burden of COPD in the U.K.: results from the confronting COPD survey. Respiratory Medicine2003;97(Suppl C):S71‐9. ">Britton 2003</a>). Because COPD is a chronic illness with frequent acute exacerbations requiring admission, a large proportion of this expense was due to secondary care costs (<a href="./references#CD009769-bbs2-0024" title="BrittonM . The burden of COPD in the U.K.: results from the confronting COPD survey. Respiratory Medicine2003;97(Suppl C):S71‐9. ">Britton 2003</a>). It is therefore useful to put any treatment reviewed into the context of hospitalisations, as well as absolute treatment effect. </p> <p>Treatment with ICS itself also represents a big cost for healthcare budgets. The now recommended (<a href="./references#CD009769-bbs2-0038" title="Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.org/. Barcelona: Global Initiative for Chronic Obstructive Lung Disease, Inc., (accessed 12 January 2011). ">GOLD 2010</a>; <a href="./references#CD009769-bbs2-0060" title="National Collaborating Centre for Acute and Chronic Conditions. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care, 2010. http://www.nice.org.uk/guidance/CG101 (accessed 7/10/13). ">NCGC 2010</a>) combination inhalers represent one of the biggest drug costs in the UK National Health Service (NHS), as their prescribing in primary care has increased in five years from GBP8 million to GBP30 million per quarter (<a href="./references#CD009769-bbs2-0061" title="National Prescribing Centre. COPD: data focused commentary. http://www.npc.nhs.uk/therapeutics/respiratory/copd/data.php (accessed 1 February 2012). ">NPC 2008</a>). </p> <p>Their effectiveness, however, is still debated (<a href="./references#CD009769-bbs2-0020" title="Anon . Preventing exacerbations in COPD. Drug and Therapeutics Bulletin2010;48(7):74‐7. ">Anon. 2010</a>; <a href="./references#CD009769-bbs2-0052" title="LucasAEM , SmeenkFWJM , SmeeleIJ , VanSchayckCP . Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients: an exploratory study. Family Practice2008;25(2):86‐91. ">Lucas 2008</a>; <a href="./references#CD009769-bbs2-0072" title="SuissaS , BarnesPJ . Inhaled corticosteroids in COPD: the case against. European Respiratory Journal2009;34(1):13‐6. ">Suissa 2009</a>; <a href="./references#CD009769-bbs2-0076" title="WelshEJ , CatesCJ , PooleP . Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2010, Issue 5. [DOI: 10.1002/14651858.CD007891.pub2] ">Welsh 2010</a>). </p> <p>Systematic reviews regarding the effectiveness and side effects of ICS in COPD have already been conducted (<a href="./references#CD009769-bbs2-0019" title="AgarwalR , AgarwalAN , GuptaD , JindalSK . Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest2010;137(2):318‐25. ">Agarwal 2010</a>; <a href="./references#CD009769-bbs2-0023" title="Bradley‐DrummondM , DasenbrookEC , PitzMW , MurphyDJ , FanE . Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta‐analysis. JAMA2008;300(20):2407‐16. ">Bradley‐Drummond 2008</a>; <a href="./references#CD009769-bbs2-0037" title="GartlehnerG , HansenRA , CarsonSS , LohrKN . Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta‐analysis of health outcomes. Annals of Family Medicine2006;4(3):253‐62. ">Gartlehner 2006</a>; <a href="./references#CD009769-bbs2-0044" title="JonesA , FayJK , BurrMI , StoneM , HoodK , RobertsG . Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD003537] ">Jones 2002</a>; <a href="./references#CD009769-bbs2-0050" title="LokeYK , KwokCS , SinghS . Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. European Respiratory Journal2010;35(5):1003‐21. ">Loke 2010</a>; <a href="./references#CD009769-bbs2-0058" title="NanniniLJ , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub3] ">Nannini 2007</a>; <a href="./references#CD009769-bbs2-0067" title="RichyF , BousquetJ , EhrlichGE , MeunierPJ , IsraelE , MorriH , et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporosis International2003;14(3):179‐90. ">Richy 2003</a>; <a href="./references#CD009769-bbs2-0068" title="RodrigoGJ , Castro‐RodriguezJA , PlazaV . Safety and efficacy of combined long‐acting beta‐agonists and inhaled corticosteroids vs long‐acting beta‐agonists monotherapy for stable COPD: a systematic review. Chest2009;136(4):1029‐38. ">Rodrigo 2009</a>; <a href="./references#CD009769-bbs2-0069" title="SelroosO , BorgstromL , IngelfJ . Use of dry powder inhalers in acute exacerbations of asthma and COPD. Therapeutic Advances in Respiratory Disease2009;3(2):81‐91. ">Selroos 2009</a>; <a href="./references#CD009769-bbs2-0071" title="SpencerS , EvansDJ , KarnerC , CatesCJ . Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD007033.pub3] ">Spencer 2011</a>; <a href="./references#CD009769-bbs2-0076" title="WelshEJ , CatesCJ , PooleP . Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2010, Issue 5. [DOI: 10.1002/14651858.CD007891.pub2] ">Welsh 2010</a>; <a href="./references#CD009769-bbs2-0078" title="YangIA , FongK , SimEHA , BlackPN , LassersonTJ . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD002991.pub2] ">Yang 2007</a>). Despite the fact that we know that different corticosteroids have different risks of adverse effects, debatably independent of their efficacy (<a href="./references#CD009769-bbs2-0018" title="AdamsN , LassersonTJ , CatesCJ , JonesPW . Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002310.pub4] ">Adams 2007</a>; <a href="./references#CD009769-bbs2-0033" title="ClarkDJ , LipworthBJ . Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax1997;52(1):55‐8. ">Clark 1997</a>; <a href="./references#CD009769-bbs2-0035" title="FabbriL , BurgePS , CroonenborghL , WarliesF , WeekeB , CiacciaA , et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax1993;48(8):817‐23. ">Fabbri 1993</a>; <a href="./references#CD009769-bbs2-0045" title="KellyHW . Comparison of inhaled corticosteroids: an update. The Annals of Pharmacotherapy2009;43(3):519‐27. ">Kelly 2009</a>; <a href="./references#CD009769-bbs2-0049" title="LipworthBJ . Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta‐analysis. Archives of Internal Medicine1999;159(9):941‐55. ">Lipworth 1999</a>; <a href="./references#CD009769-bbs2-0054" title="MartinRJ , SzeflerSJ , ChinchilliVM , KraftM , DolovichM , BousheyHA , et al. Systemic effect comparisons of six inhaled corticosteroid preparations. American Journal of Respiratory Care Medicine2002;165(10):1377‐83. ">Martin 2002</a>; <a href="./references#CD009769-bbs2-0075" title="WalesD , MakkerH , KaneJ , McDowellP , O'DriscollBR . Systemic bioavailability and potency of high‐dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers. Chest1999;115(5):1278‐84. ">Wales 1999</a>), none of the systematic reviews separated the different corticosteroids in their analysis. This issue was also raised by the last NICE COPD guideline development group (<a href="./references#CD009769-bbs2-0060" title="National Collaborating Centre for Acute and Chronic Conditions. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care, 2010. http://www.nice.org.uk/guidance/CG101 (accessed 7/10/13). ">NCGC 2010</a>). </p> <p>Separate analyses of these commonly used corticosteroids are needed. They are expensive and questions have been raised about their effectiveness; therefore, it is worth considering beclometasone, one of the cheaper, less potent and already widely used ICS. The current review will therefore concentrate on beclometasone dipropionate and the evidence for its use versus placebo. As the current recommendation is to combine corticosteroids with LABAs, we will also review the comparison between combined beclometasone dipropionate/LABAs and LABAs alone. The new guidance recommending inhaled corticosteroids with long‐acting anticholinergics was published too late to be added as a third comparison. </p> <p>As clinical decisions are based on effectiveness, risk of adverse effects and cost, this review will have implications for treatment choices. It is hoped that this review will stimulate future reviews that will look separately at the other ICS, so that these can then be synthesised as head‐to‐head comparisons. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009769-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009769-sec-0028"></div> <p>To determine the effectiveness and safety in COPD of inhaled beclometasone alone compared with placebo, and of inhaled beclometasone in combination with LABAs compared with LABAs alone. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009769-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009769-sec-0029"></div> <section id="CD009769-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009769-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) of parallel and cross‐over design.</p> <p>We included only double‐blinded studies. For studies with ambiguous use of the term "blinding" or no mention of blinding at all, we assessed the risk of bias according to the specific outcome that it could have influenced. We excluded cluster‐randomised trials. </p> <p>The length of follow‐up had to be at least 12 weeks.</p> </section> <section id="CD009769-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adult patients (&gt; 35 years old) with an established diagnosis of stable COPD fulfilling the international guidelines, or equivalent guidelines. We assessed and discussed older studies that may not comply with current GOLD standards. </p> <p>We excluded studies on COPD due to homozygous alpha‐1‐antitrypsin deficiency, as this is a rare genetic cause, and patients with this disorder may respond differently from those with COPD due to environmental risk factor exposure. </p> <p>Patients could not have any other significant diseases that could affect measured outcomes, such as asthma or other respiratory diseases. </p> </section> <section id="CD009769-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD009769-list-0001"> <li> <p>Intervention: beclometasone administered by inhalation devices including metered dose inhalers, dry powder inhalers or spacer devices, but excluding nebulisers. We also considered co‐therapy with a long‐acting beta<sub>2</sub>‐agonist (LABA) as long as it was used in both treatment and control arms of the trials. </p> </li> <li> <p>Comparison: placebo.</p> </li> </ol> </p> <p>We included studies with concurrent therapies and planned to investigate these by performing a subgroup analysis. </p> </section> <section id="CD009769-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD009769-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009769-list-0002"> <li> <p>Change in lung function (FEV<sub>1</sub>, FEV<sub>1</sub>/FVC). </p> </li> <li> <p>Mortality (all‐cause and respiratory).</p> </li> <li> <p>Pneumonia.</p> </li> </ol> </p> </section> <section id="CD009769-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009769-list-0003"> <li> <p>Exercise capacity—e.g. six‐minute walk test (6MWT).</p> </li> <li> <p>Number of participants experiencing one or more exacerbations of COPD (defined as worsening of the condition requiring hospitalisation or treated by oral steroids and/or antibiotics). </p> </li> <li> <p>Number of exacerbations of COPD (defined as worsening of the condition requiring hospitalisation, treated by oral steroids and/or antibiotics). </p> </li> <li> <p>Hospitalisations and length of stay.</p> </li> <li> <p>Quality of life—St. George's Respiratory Questionnaire (SGRQ), Chronic Respiratory Disease Questionnaire (CRDQ). (We will exclude non–disease‐specific scales, such as the Short Form (36) Health Survey (SF‐36).) </p> </li> <li> <p>Symptoms—e.g. change in Transitional Dyspnoea Index (TDI).</p> </li> <li> <p>Use of rescue bronchodilators.</p> </li> <li> <p>Other adverse events: oropharyngeal side effects (candidiasis, dysphonia), osteopoenia measures (bone fractures, bone density), diabetes, palpitations, tremor, skin bruising, plasma cortisol levels and cataracts. </p> </li> <li> <p>Withdrawal.</p> </li> </ol> </p> </section> </section> </section> <section id="CD009769-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>The search methods were formulated according to the template produced by the Cochrane Airways Group (<a href="./references#CD009769-bbs2-0030" title="Cochrane Airways Group. Developing a search strategy for an Airways Group systematic review. http://airways.cochrane.org/authors (accessed 2 January 2012). ">CAG 2008</a>). The Cochrane Airways Group's Trials Search Co‐ordinator (TSC) performed the search and supplied the results to the review author for the study selection process. </p> <section id="CD009769-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We identified trials using the Cochrane Airways Group Specialised Register of trials (CAGR). This database is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and from handsearching of respiratory journals and meeting abstracts (see <a href="./appendices#CD009769-sec-0125">Appendix 1</a>). We searched all records in the Specialised Register coded as 'COPD' using the following terms:  </p> <p><i>(*steroid or steroid* or corticosteroid* or beclo* or beco* or asmabec or clenil or qvar or fostair).</i> </p> <p>We reviewed clinical guidelines and review articles for references by searching GOLD and NICE guidelines and conducting a search of the Centre for Reviews and Dissemination (CRD), Cochrane Database of Systematic Reviews (CDSR) and Turning Research Into Practice (TRIP) databases. </p> <p>For grey literature, we searched the OpenGrey database, Zetoc and Web of Science for conference abstracts, and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), clinicaltrials.gov, clinicaltrialsregister.eu, the National Research Register (NRR) archive and the International Federation of Pharmaceutical Manufacturers &amp; Associations (IFPMA) Clinical Trials Portal for ongoing or completed studies. </p> <p>We searched available pharmaceutical trial registers (AstraZeneca, Bayer, Bristol‐Myers Squibb, GlaxoSmithKline, Novartis, Roche, UCB). </p> <p>We searched all databases from their inception to the present and imposed no restriction on language of publication. </p> </section> <section id="CD009769-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We reviewed reference lists of all primary studies for additional references. We contacted authors of identified trials and asked them to identify other published and unpublished studies. We also contacted manufacturers of any beclometasone inhalers past or present (Chiesi, UCB Pharma, 3M, Teva, GlaxoSmithKline and Merck/MSD) and obtained licensing information from the US Food and Drug Administration (FDA) through its website and from the UK Medicines and Healthcare products Regulatory Agency (MHRA) through a Freedom of Information request. </p> <p>As this is a review of drug trials, and in most Western countries, these need both drug trial authorisation and ethics approval, we additionally contacted marketing authorisation bodies and/or central Ethics Committees for the European Union (EMA/EudraCT), the UK (MHRA and NRES), Armenia (SCDMT), Austria (AGES), Azerbaijan (DVAEM), Belarus (RCETH), Belgium (FAGG‐AFMPS), Bulgaria (BDA), Croatia (ALMP and MoH), Cyprus (PHS), Denmark (Lægemiddelstyrelsen), Estonia (SAM), Finland (FIMEA), Georgia (MoH), Germany (BfArM), Greece (EOF), Hungary (OGYI), Iceland (Visindasidanefnd, Lyfjastofnun), Ireland (IMB), Italy (AIFA), Kazakhstan (DARI), Kyrgyzstan (MoH), Latvia (ZVA), Lithuania (VVKT, LBEK), Luxemburg (DPM, CNER), Malta (Medicines Authority, MHEC), Moldova (AMED), Netherlands (CCMO), Norway (Legemiddelver), Poland (URPL), Portugal (INFARMED, CEIC), Romania (ANM, CNESCM), Russia (Roszdravnadzor, Rosminzdrav), Serbia (ALIMS), Slovakia (SUKL), Slovenia (JAZMP, NMEC), Spain (AEMPS), Sweden (MPA), Switzerland (Swissmedic), Tajikistan (MoH), Turkey (IEGM), Ukraine (DEC, MoZ), the USA (FDA), Uzbekistan (Uzpharm), China (SFDA), India (CDSCO), South Africa (MMC, NHREC), Mexico (MoH, INER, IMIC), New Zealand (MEDSAFE, HDEC) and Australia (TGA, NAA), and the following ethics committee organisations: Association of Research Ethics Committees (AREC), Forum for Ethical Review Committees in the Asian &amp; Western Pacific Region (FERCAP), Forum for Ethics Committees in the Confederation of Independent States (FECCIS), Latin American Forum of Ethics Committees in Health Research (FLACEIS), Pan‐African Bioethics Initiative (PABIN), Council on Health Research for Development (COHRED) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). </p> <p>We citation‐tracked identified studies to identify further studies.</p> </section> </section> <section id="CD009769-sec-0040"> <h3 class="title" id="CD009769-sec-0040">Data collection and analysis</h3> <section id="CD009769-sec-0041"> <h4 class="title">Selection of studies</h4> <p>One review author (DADC or NT) identified titles and abstracts that appeared to be relevant. We retrieved the full‐text trial reports, and two of us (DADC and MJ, or DADC and NT) independently assessed for inclusion all potential studies that we had identified as a result of the search strategy. We recorded excluded reviews that may appear to be relevant, along with an explanation for their exclusion. We resolved any disagreement through discussion or, if required, by consulting a third person, who is an expert in the field. </p> </section> <section id="CD009769-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two of us (DADC and MJ) extracted data from the selected studies using a data extraction form (initial outline: see <a href="./appendices#CD009769-sec-0131">Appendix 2</a>), which was first piloted. When any doubt arose, we sought an expert opinion. One of us then entered data into Review Manager 5 (<a href="./references#CD009769-bbs2-0066" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>), and a second review author checked this work. We obtained data missing from publication through correspondence with the study authors, using multiple media (electronic mail, letter, telephone), in all possible circumstances. </p> </section> <section id="CD009769-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two of us (DADC and NT) independently assessed risk of bias for each study using the criteria and tools outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions </i>(<a href="./references#CD009769-bbs2-0041" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD009769-sec-0132">Appendix 3</a>). We resolved any disagreement by discussion or by involving a third assessor (MJ and, if necessary, our expert). We assessed the risk of bias according to the following domains. </p> <p> <ol id="CD009769-list-0004"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear risk of bias.</p> </section> <section id="CD009769-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data (such as exacerbations of COPD and pneumonia) using odds ratios (ORs) with 95% confidence intervals (CIs). We used the Mantel‐Haenszel method to combine estimates of ORs, except for rare events, for which the Peto method is more suitable. </p> <p>We assessed continuous data (such as lung function, exercise capacity, quality of life and symptoms) using mean differences (MDs) (also known as "differences in means" or "weighted mean differences" (WMDs)) for absolute differences between mean values, or standardised mean difference (SMDs) for outcomes measured in different ways. When rate ratios were reported, we used the generic inverse variance (GIV) method. </p> <p>We expressed time‐to‐event data (e.g. mortality) as a hazard ratio (HR), with a proportional hazards assumption. </p> </section> <section id="CD009769-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We rigorously assessed cross‐over design studies on intervention and wash‐out periods, using expert input, as corticosteroids can have long‐lasting effects. Any cross‐over studies that were deemed not suitable were treated as parallel studies by including data from only the first period of the trial, before the cross‐over. </p> <p>In studies with multiple treatment groups, we determined which intervention groups were relevant to this systematic review, and for which particular meta‐analysis. To avoid double‐counting, we divided the control group according to the number of interventions in the study. </p> <p>We counted exacerbations as participants with one or more exacerbation(s); grouping together participants with one or multiple exacerbations prevented double‐counting of participants. </p> </section> <section id="CD009769-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>When missing statistics could not be obtained from the trial authors, we used the reported CI or P value to calculate standard deviations (SDs) or standard errors (SEs). </p> <p>We accounted for missing participants according to intention‐to‐treat (ITT) analysis, as well as the secondary outcome measure of "withdrawals". </p> <p>We contacted trial authors to obtain missing data and clarify information on study design. Where quotes from correspondence have been used, permission from the author was obtained. </p> </section> <section id="CD009769-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to assess statistical variation. If we identified substantial heterogeneity, we explored this by performing a prespecified subgroup analysis.<b> </b> </p> </section> <section id="CD009769-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>When we suspected reporting bias, we contacted study authors to ask them to provide missing outcome data. When this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by conducting a sensitivity analysis<b>. </b> </p> <p>We assessed publication bias using a funnel plot and interpretation, as asymmetry in the funnel plot is not necessarily caused by publication bias. However, funnel plots are suitable only for assessment of ten or more studies. </p> </section> <section id="CD009769-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We created a 'Summary of findings' table by using the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions </i>(<a href="./references#CD009769-bbs2-0041" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>), and by using GRADEpro software. We included the following outcomes. </p> <p> <ol id="CD009769-list-0005"> <li> <p>Change in lung function (FEV<sub>1</sub>, FEV<sub>1</sub>/FVC). </p> </li> <li> <p>Mortality (all‐cause and respiratory).</p> </li> <li> <p>Pneumonia.</p> </li> <li> <p>Exacerbations of COPD.</p> </li> <li> <p>Adverse events.</p> </li> <li> <p>Withdrawals.</p> </li> </ol> </p> </section> <section id="CD009769-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We analysed the data using the following subgroups.</p> <p> <ol id="CD009769-list-0006"> <li> <p>Dose of beclometasone (e.g. above and below 800 μg, as the lower‐strength beclometasone dipropionate products such as the now discontinued Becotide 200 were commonly prescribed up to this dose). </p> </li> <li> <p>Delivery method of beclometasone (metered dose inhalers, dry powder inhalers or spacer devices). </p> </li> <li> <p>Medium‐term (between three and six months) and long‐term (greater than six months) treatment periods. </p> </li> <li> <p>Severity of condition at baseline according to GOLD criteria.</p> </li> <li> <p>Prior use of ICS (dichotomised as yes/no).</p> </li> <li> <p>Concurrent therapy: theophylline (dichotomised as yes/no).</p> </li> </ol> </p> </section> <section id="CD009769-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the sensitivity to degree of bias of our primary outcomes by comparing overall results with those obtained exclusively from trials assessed as being at low risk of bias for the domains "randomisation" and "blinding". We compared the results from the fixed‐effect model with results from the random‐effects model. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009769-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009769-sec-0052"></div> <section id="CD009769-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD009769-sec-0054"> <h4 class="title">Results of the search</h4> <p>As recommended by the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement (<a href="./references#CD009769-bbs2-0057" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] ">Moher 2009</a>), a study flow diagram has been included (<a href="#CD009769-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009769-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram." data-id="CD009769-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> </div> <p>We identified 1243 records through database searching (CAGR, Zetoc, Web of Science, clincialtrials.gov, clinicaltrialsregister.eu, OpenGrey, WHO ICTRP, IFPMA, NRR archive, pharmaceutical trial registers, GOLD, NICE, CRD, CDSR, TRIP) and 511 through other sources (FDA; MHRA; personal communication; manufacturers/pharmaceutical companies; marketing authorisation/ethics committee organisations; using included trials to contact authors, review the reference lists and perform citation‐tracking for additional studies). (See <a href="#CD009769-fig-0001">Figure 1</a> and, for a detailed break‐down, <a href="#CD009769-fig-0002">Figure 2</a>.) Based on title and abstract, 16 studies met our inclusion criteria. After the full‐text articles were assessed, four studies were deemed suitable for inclusion: <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>, <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a>, the unpublished <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> and the ongoing <a href="./references#CD009769-bbs2-0017" title="SinghD , KampschulteJ ,  WedzichaJA ,  JonesPW ,  CohuetG ,  CorradiM ,  etal . A trial of beclomethasone/formoterol in COPD using EXACT‐PRO to measure exacerbations. European Respiratory Journal2013;41(1):12‐7. [DOI: 10.1183/09031936.00207611; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/22653766] WedzichaWA . BDP/FF versus formoterol fumarate (FF) in patients with severe COPD (lung function and exacerbation rate). http://clinicaltrials.gov/ct2/show/NCT00929851 (accessed 26 June 2013). ">Wedzicha (FORWARD) 2013</a>. We obtained the unpublished Derenne full‐text study from the authors and requested additional data from the authors of the Weir study to include their data in the meta‐analysis (currently possible only for withdrawals). This was promised to us but is still pending. </p> <div class="figure" id="CD009769-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Detailed break‐down of results of the search strategy." data-id="CD009769-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Detailed break‐down of results of the search strategy.</p> </div> </div> </div> </section> <section id="CD009769-sec-0055"> <h4 class="title">Included studies</h4> <p>Three studies were included (<a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>; <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a>; <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a>), the characteristics of which are described in detail in the <a href="./references#CD009769-sec-0140" title="">Characteristics of included studies</a> tables. </p> <section id="CD009769-sec-0056"> <h5 class="title">Calverley 2010</h5> <p><a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> was a nearly year‐long (48 weeks) double‐blind randomised controlled trial that examined the effect of the new drug beclometasone/formoterol (BDP/FF) pMDI (pressurised metered dose inhaler) with a daily dose of 400/24 μg, against the effect of a formoterol (FF) DPI (dry powder inhaler) with a daily dose of 24 μg. (These are normal maximum dosages for BDP/FF and FF (<a href="./references#CD009769-bbs2-0038" title="Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.org/. Barcelona: Global Initiative for Chronic Obstructive Lung Disease, Inc., (accessed 12 January 2011). ">GOLD 2010</a>)). It investigated 476 (BDP/FF 237, FF 239) participants in 8 European countries, who had a mean age of 63.0 ± 9.5 years and were selected for COPD according to near‐accurate GOLD guidelines (a 30‐minute postbronchodilator (post‐BD) change in FEV<sub>1</sub> of less than 12% was required, although GOLD standards specify 10 to 15 minutes post‐BD). This was a study of participants with stage 3 (severe) COPD (a post‐BD FEV<sub>1</sub> between 30% and 50% of the predicted normal). Participants were required to have been stable for a two‐month run‐in period. The trial required a pack‐year history of at least 20 years for inclusion, with two‐thirds of participants being ex‐smokers. The outcomes of interest measured were pulmonary function tests (FEV<sub>1</sub>); mean rate of COPD exacerbations; Modified Medical Research Council dyspnoea score questionnaire; St. George’s Respiratory Questionnaire (CRDQ) to gauge quality of life; exercise capacity using the six‐minute walking test (6MWT); a body mass index, airflow obstruction, dyspnoea and exercise capacity index (BODE); use of rescue bronchodilator and several adverse events. Withdrawal and mortality were deduced by the review authors (DADC, MJ) from the data, using the numbers quoted in the text and in the tables. </p> <p>The trial contained a third treatment arm (comparing both BDP/FF and FF in separate inhalers with budesonide/formoterol (242 participants randomly assigned)), but this comparison was not relevant for this review. </p> </section> <section id="CD009769-sec-0057"> <h5 class="title">Derenne 1995</h5> <p>The <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> study previously appears in the literature only as a conference abstract but as part of another meta‐analysis (<a href="./references#CD009769-bbs2-0074" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta‐analysis. Thorax1999;54(1):7‐14. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10343624] ">van Grunsven 1999</a>), which was performed to look summatively at several different ICS. The original full‐text article, however, has not been published. Several of the <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> authors are co‐authors in that meta‐analysis, which implies that they worked closely with the latter group to lend them their data. However, it is not possible to separate out the <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> data retrospectively from data from the other studies, all of which address different ICS than BDP. Although we contacted the <a href="./references#CD009769-bbs2-0074" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta‐analysis. Thorax1999;54(1):7‐14. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10343624] ">van Grunsven 1999</a> authors, it was also not possible to obtain the original Derenne data from them. As stated above, however, we were successful in obtaining two different versions of the unpublished full‐text article; one from <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> co‐author T. Similowski (without figures, but with additional appendices) (Personal communication by email, 15/05/2012), and one as a chapter in the thesis of P.M. van Grunsven, available online (with figures, but without appendices; minor improvements in the abstract), also found by T. Similowski (Personal communication by email, 4/12/12). </p> <p><a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> investigated beclometasone versus placebo. This was a 2‐year‐long study based in France that compared beclometasone dipropionate (Becotide) 1500 μg daily with placebo. This is a high‐dose study: 1500 μg is considerably more than the maximum 1000 μg per day recommended at the time, received through equivalent chlorofluorocarbon (CFC) inhalers (<a href="./references#CD009769-bbs2-0028" title="British Thoracic Society Standards of Care Committee. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax1997;52(Suppl 5):S1‐8. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1765890/; PMCID: PMC1765890] ">BTS 1997</a>), which may be substantially different from currently used hydrofluoroalkane (HFA) beclometasone inhalers (<a href="./references#CD009769-bbs2-0048" title="LeachCL , DavidsonPJ , BoudreauRJ . Improved airway targeting with the CFC‐free HFA–beclomethasone metered‐dose inhaler compared with CFC–beclomethasone. European Respiratory Journal1998;12:1346–53. [DOI: 10.1183/09031936.98.12061346; PUBMED: 9877489] ">Leach 1998</a>). A total of 100 participants using BDP were randomly assigned versus 94 participants receiving placebo, with average age around 63 years (BDP 62 (SD 7); placebo 63 (SD 8)). It is not clear from the text whether concomitant drug use (of theophyllines, of anticholinergics, etc.) was ceased at the start of the trial. The diagnostic criteria used included the <a href="./references#CD009769-bbs2-0021" title="American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. American Review of Respiratory Disease1987;136:225‐43. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/3605835] ">ATS 1987</a> guidelines (of a clinical diagnosis of COPD based on history) and staging of pre‐bronchodilator FEV<sub>1</sub> that was 30% to 60% of predicted (this compares with modern GOLD stage 3 COPD of 30% to 50% predicted and the remainder (50% to 60% predicted) falling within GOLD stage 2). Participants had to have 10‐minute postbronchodilator reversibility less than 15% of the predicted FEV<sub>1</sub>. This trial included smokers, ex‐smokers and non‐smokers; most participants were ex‐smokers. Outcomes of interest were post‐BD FEV<sub>1</sub>; exacerbations, defined as "prescribed courses of antibiotics or oral corticosteroids"; Fletcher Dyspnoea Scale scores (<a href="./references#CD009769-bbs2-0036" title="FletcherCM , JonesNL , BurrowsB , NidenAH . American emphysema and British bronchitis: a standardized comparative study. American Review of Respiratory Disease1964;90:1‐13. ">Fletcher 1964</a>); hospitalisation and duration; adverse events; and withdrawal and mortality (both deduced by the review authors (DADC, MJ)). </p> </section> <section id="CD009769-sec-0058"> <h5 class="title">Weir 1999</h5> <p>The <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> study compared beclometasone only versus placebo. It was a 2‐year‐long double‐blind parallel randomised placebo‐controlled trial based in the UK that investigated the effect of a daily dose of 1500 μg of BDP if participants' weight  was below 50 kg, and 2000 μg if weight was over 50 kg. The control was a placebo inhaler, with an equivalent weight‐based number of puffs. Participants who were taking oral theophyllines before the study maintained the same dose throughout the study. The number of participants randomly assigned was 98 (BDP n = 49, placebo n = 49), and they had an average age of 66 years. The diagnostic criteria included a clinical diagnosis of COPD, adult‐onset airflow obstruction with FEV<sub>1</sub> &lt; 70% predicted and FEV<sub>1</sub>/FVC ratio &lt; 65%. Patients were excluded if they had clinically significant bronchodilator reversibility or a history of significant improvement with steroid treatment; or if steroid treatment was clinically indicated. Other criteria for exclusion included prescribed use of any form of corticosteroid therapy for longer than three months in the previous year or prescribed use of any form of steroid therapy during the 4‐week run‐in period. This trial included smokers and ex‐smokers, but most participants were ex‐smokers. The outcomes of interest included change in post‐BD FEV<sub>1</sub>, rate of exacerbations (no description of what was defined as an exacerbation was provided), change in BDI (Baseline Dyspnoea Index) or CRDQ (in a subgroup of participants, but data declared as not reported in this publication) and withdrawal. </p> </section> </section> <section id="CD009769-sec-0059"> <h4 class="title">Excluded studies</h4> <p>A detailed description of excluded studies is provided in the <a href="./references#CD009769-sec-0141" title="">Characteristics of excluded studies</a> tables. </p> <p>One study had inadequate inclusion criteria to exclude asthmatic patients (<a href="./references#CD009769-bbs2-0004" title="Boothman‐BurrellD , DelanySG , FlanneryEM , HancoxRJ , TaylorDR . The efficacy of inhaled corticosteroids in the management of non asthmatic chronic airflow obstruction. New Zealand Medical JournalOctober 1997;110(1053):370‐3. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/9364183] ">Boothman‐Burrell 1997</a>), four studies were excluded because they were not randomised trials (<a href="./references#CD009769-bbs2-0005" title="DincM ,  TchugunovaY ,  DincS ,  CinarliB ,  AtaseverT ,  OzM . Decreased osteocalcin levels in patients with chronic obstructive pulmonary disease using long‐term inhaled beclomethasone dipropionate. Metabolism: Clinical and Experimental2001;50(11):1336‐9. [DOI: 10.1053/meta.2001.27231; http://www.sciencedirect.com/science/article/pii/S0026049501997914; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/11699053] ">Dinc 2001</a>; <a href="./references#CD009769-bbs2-0007" title="MiravitllesM , Alvarez SalaJL , LamarcaR , FerrerM , MasaF , VereaH . Treatment and quality of life in patients with chronic obstructive pulmonary disease. Quality of Life Research2002;11(4):329‐38. ">Miravitlles 2002</a>; <a href="./references#CD009769-bbs2-0010" title="StruijsA , MulderH . The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1‐year study of beclomethasone versus budesonide. Netherlands Journal of Medicine1997;50(6):233‐7. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/9232087] ">Struijs 1997</a>; <a href="./references#CD009769-bbs2-0013" title="vanSchayckCP , DompelingE , RuttenMP , FolgeringH , van denBoomG , vanWeelC . The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest1995;107(5):1199‐205. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/7750306] ">van Schayck 1995</a>), two were not double‐blinded (<a href="./references#CD009769-bbs2-0008" title="OuyangR , YinB . Clinical study of inhaled corticosteroid in non‐asthmatic chronic obstructive pulmonary disease. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih1998;21(8):497‐9. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/11360524] ">Ouyang 1998</a> after translation, <a href="./references#CD009769-bbs2-0009" title="ShmelevEI , KunicinaYL . Comparison of fenspiride with beclomethasone as adjunctive anti‐inflammatory treatment in patients with chronic obstructive pulmonary disease. Clinical Drug Investigation2006;26(3):151‐9. [http://adisonline.com/druginvestigation/Abstract/2006/26030/Comparison_of_Fenspiride_with_Beclomethasone_as.5.aspx] ">Shmelev 2006</a>), three had treatment periods that were too short (<a href="./references#CD009769-bbs2-0011" title="ThompsonAB , MuellerMB , HeiresAJ , BohlingTL , DaughtonD , YanceySW , et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. American Review of Respiratory Disease1992;146(2):389‐95. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/1489129] ">Thompson 1992</a>; <a href="./references#CD009769-bbs2-0014" title="WeirDC , GoveRI , RobertsonAS , BurgePS . Corticosteroid trials in non‐asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax1990;45(2):112‐17. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC462320/; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/2180105] ">Weir 1990</a>; <a href="./references#CD009769-bbs2-0015" title="WeirDC , BurgePS . Effects of high dose inhaled beclomethasone dipropionate 750 μg and 1500 μg twice daily and 40 mg oral prednisolone on lung function, symptoms and bronchial hyperresponsiveness in patients with non‐asthmatic airflow obstruction. Thorax1993;48(4):309‐16. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC464423/; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/8511727] ">Weir 1993</a>) and one did not address the appropriate research question (<a href="./references#CD009769-bbs2-0012" title="TzaniP , CrisafulliE , NicoliniG , AielloM , ChettaA , CliniEM , et al. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2011;6:503‐9. [DOI: 10.2147/COPD.S23746; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206766/] TzaniP , CrisafulliE , NicoliniG , CliniE , AielloM , ChettaA , et al. Reduction in air trapping and dyspnea with an extrafine combination of beclomethasone and formoterol in COPD [Abstract]. European Respiratory Society 20th Annual Congress; 2010 September 18‐22; Barcelona. ">Tzani 2011</a>). Last, one study was excluded because of insufficient data (<a href="./references#CD009769-bbs2-0006" title="JohnM , BosseS , OltmannsU , SchumacherA , WittC . Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respiratory Medicine2005;99(11):1418‐24. [DOI: 10.1016/j.rmed.2005.03.034; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/15894479] JohnM , BosseS , SchumacherA , OltmannsU , WittC . Effect of inhaled beclomethasone HFA 134 (QVAR/Ventolair) on health related quality of life in patients with chronic obstructive pulmonary disease [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. [A43] [Poster: F43]. ">John 2005</a>); expert opinion was that the wash‐out period in this cross‐over trial was insufficient, and therefore, as per protocol, we would try to include it as a parallel trial, using only data from the first treatment period. However, when the trial authors were contacted, they were unable to provide data from the first treatment period only. </p> <section id="CD009769-sec-0060"> <h5 class="title">Ongoing studies</h5> <p>One ongoing study was identified as potentially relevant (<a href="./references#CD009769-bbs2-0017" title="SinghD , KampschulteJ ,  WedzichaJA ,  JonesPW ,  CohuetG ,  CorradiM ,  etal . A trial of beclomethasone/formoterol in COPD using EXACT‐PRO to measure exacerbations. European Respiratory Journal2013;41(1):12‐7. [DOI: 10.1183/09031936.00207611; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/22653766] WedzichaWA . BDP/FF versus formoterol fumarate (FF) in patients with severe COPD (lung function and exacerbation rate). http://clinicaltrials.gov/ct2/show/NCT00929851 (accessed 26 June 2013). ">Wedzicha (FORWARD) 2013</a>) (see <a href="./references#CD009769-sec-0143" title="">Characteristics of ongoing studies</a>). It was a 48‐week double‐blind trial with 1119 participants in 5 European countries of BDP/FF 100 µg/6 µg (daily dose not known yet) versus FF 12 µg (cf. the included <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>). Participants had to have severe COPD and had to be older than 40 years of age. Outcomes of potential interest would include exacerbation rate; change in FEV<sub>1</sub>; further lung measurements; SQRQ; and use of rescue inhalers. </p> <p>The study will be known as "FORWARD" (Foster 48‐Week Trial to Reduce Exacerbations in COPD); investigators were expected to report at "the ATS in May" 2012, and the article was to be published later (Personal communication by email, 19/03/13). </p> </section> <section id="CD009769-sec-0061"> <h5 class="title">Studies awaiting classification</h5> <p>One study is awaiting classification (<a href="./references#CD009769-bbs2-0016" title="VengerovB . Effectiveness of long‐term treatment with inhaled corticosteroids in metal workers with COPD. European Respiratory Journal Supplement1998;12(Suppl 28):413S. ">Vengerov 1998</a>), as only the abstract is currently available, and it does not contain enough information regarding trial design, blinding, inclusion criteria and minimum age of participants to allow the study to be assessed for inclusion (see <a href="./references#CD009769-sec-0142" title="">Characteristics of studies awaiting classification</a>). It is a 5‐year "randomised prospective trial" of 89 non‐smoking metal workers in Ukraine with COPD due to industrial pollution, with an FEV<sub>1</sub> of 46% to 70% predicted. The trial investigated a daily dose of 750 to 1250 μg beclometasone dipropionate versus observation, and potential outcomes of interest were change in FEV<sub>1</sub>; number of exacerbations; length of hospitalisations; and symptom score. We tracked down the trial author, who now works in a different country and has promised to get the Russian full‐text article to us (Personal communication by email, 12/11/12) but has not yet done so. This may also be in investigation into a different form of COPD—a form caused by industrial mining. </p> </section> </section> </section> <section id="CD009769-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>A detailed description of the risk of bias assessments per study is presented in the <a href="./references#CD009769-sec-0140" title="">Characteristics of included studies</a> section and is graphically summarised below (<a href="#CD009769-fig-0003">Figure 3</a> and <a href="#CD009769-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD009769-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about all risk of bias items presented as percentages across all included studies." data-id="CD009769-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about all risk of bias items presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009769-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009769-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009769-sec-0063"> <h4 class="title">Allocation</h4> <p>In <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>, methods to reduce risk of selection bias were adequately described. The random sequence was generated by a centralised computerised system and was used to allocate participants for concealment of allocation. </p> <p><a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> and <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> provided insufficient information on randomisation, with the former having inadequate information regarding rigorous methods to conceal allocation, and the authors of the latter providing evidence of central allocation and further allocation concealment in a personal communication. </p> </section> <section id="CD009769-sec-0064"> <h4 class="title">Blinding</h4> <p>In both <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> and <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a>, blinding of both participants and personnel and blinding during the measurements were adequate. </p> <p><a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> provided insufficient detail to allow conclusions to be drawn on blinding adequacy, but study drugs were "supplied" to the personnel, implying the possibility that adequate blinding of personnel and participants was maintained. </p> </section> <section id="CD009769-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> was deemed at low risk of attrition bias. Missing information was dealt with in an ITT analysis using the last observation carried forward (LOCF) method. </p> <p><a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> and especially <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> suffered from high withdrawal rates. <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> warns that because of the reduced number of measurements used in the multivariate analysis, FEV<sub>1</sub> results should be interpreted with caution. Although risk of bias due to withdrawal of the most severely affected participants in <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> was minimised (because the numbers of withdrawals from each arm was balanced and, if the risk of bias was present, it would underestimate the effect of BDP treatment), Weir did not perform a conventional ITT analysis but analysed only participants with at least 12 months' follow‐up (i.e. only participants who completed at least half the length of the study). </p> </section> <section id="CD009769-sec-0066"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> referred to a protocol‐like trial record in the full text and described only minor differences from all versions of this trial record. <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> was compared with an earlier abstract publication and was deemed at low risk of reporting bias. </p> <p><a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> did not report the final numbers used in each treatment arm of their analysis (only participants with at least 12 months' follow‐up were analysed) and did not report the Guyatt questionnaire data, as recording of these measures was compromised by lack of clinical staff during a period of the trial. </p> </section> <section id="CD009769-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> was funded by Chiesi. This was declared in the paper, as was conflict of interest information. </p> <p><a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> was funded by GlaxoWellcome France, which was declared. As it was an original manuscript, risk of publication bias was minimal. </p> <p><a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a>, however, declared neither their funding information (GlaxoWellcome was involved in randomisation, provision of the drugs and performance of the analysis) nor conflicts of interest. Authors also "... had great difficulty in getting the paper published; it was turned down by many journals and was published as an extended conference proceeding where the requirements were for a cut‐down paper" (Personal communication by email, P.S. Burge, 20/12/12). This would explain the lack of many methodological details in the full text. </p> </section> </section> <section id="CD009769-sec-0068"> <h3 class="title" id="CD009769-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD009769-tbl-0001"><b>Summary of findings for the main comparison</b> Beclometasone/LABA compared with LABA for COPD</a>; <a href="./full#CD009769-tbl-0002"><b>Summary of findings 2</b> Beclometasone compared with placebo for COPD</a> </p> <p>Because of incomplete reporting in Weir and the unfinished Wedzicha study, only the Calverley and Derenne studies were included quantitatively for most outcomes, and Weir was included narratively in the review (except for withdrawals). As Calverley addresses a different research question from that pursued by Derenne and Weir, the only meta‐analysis was performed on these latter two, and only for the withdrawals outcome. (For a full discussion on whether to combine these research questions into a meta‐analysis, see <a href="#CD009769-sec-0108">Overall completeness and applicability of evidence</a>. For a full discussion of why the meta‐analysis could be done only for withdrawals, see this outcome under <a href="#CD009769-sec-0068">Effects of interventions</a>.) </p> <p>As only one trial per review arm was analysed quantitatively, we did not carry out any of the planned subgroup analyses or sensitivity analyses. </p> <p>The readers are reminded that current international guidelines do not recommend the use of beclometasone alone (or any ICS) without LABA in COPD (<a href="./references#CD009769-bbs2-0022" title="American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients With COPD. 1.2. New York: American Thoracic Society, 2004. ">ATS/ERS 2004</a>; <a href="./references#CD009769-bbs2-0039" title="Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.org/ (accessed 7 October 2013). ">GOLD 2013</a>). </p> <section id="CD009769-sec-0069"> <h4 class="title">Primary outcomes</h4> <section id="CD009769-sec-0070"> <h5 class="title">Difference in lung function</h5> <section id="CD009769-sec-0071"> <h6 class="title">Beclometasone versus placebo</h6> <p>Using the absolute value of change in lung function, at 2 years, the <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> study (n = 194 participants) reported a statistically non‐significant change in (postbronchodilator) FEV<sub>1</sub> of 0.03 litres (95% CI ‐0.25 to 0.31, P = 0.83] for BDP compared with placebo. </p> <p>At only 1 year, Derenne showed a statistically non‐significant (ns) change of ‐0.07 (95% CI ‐0.35 to 0.21, P = 0.63] for BDP compared with placebo. </p> <p>These two results are shown in <a href="./references#CD009769-fig-0005" title="">Analysis 1.1</a>, where 1‐year and 2‐year results have not been combined into an overall effect, as they are measurements taken at different time points in the same participants. </p> <p>At 2 years, the <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> study reported a statistically non‐significant slower mean rate decline of FEV<sub>1</sub> in BDP compared with placebo with 95% CI ‐0.080 to +0.008 L/y. This is derived from its unconventional intention‐to‐treat analysis of only participants who completed a full year of the study (n = 78). No point estimate was given. </p> </section> <section id="CD009769-sec-0072"> <h6 class="title">Beclometasone/LABA versus LABA</h6> <p>At 48 weeks, the <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 465) study reported a statistically significant increase in FEV<sub>1</sub> of 0.051 L (95% CI 0.001 to 0.102, P = 0.046) for BDP/LABA versus LABA, which is unlikely to be clinically significant (a change of 0.200 L; <a href="./references#CD009769-bbs2-0031" title="CazzolaM , MacNeeW , MartinezFJ , RabeKF , FranciosiLG , BarnesPJ , et al. American Thoracic Society, European Respiratory Society Task Force on Outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal2008;31(2):416‐69. [DOI: 10.1183/09031936.00099306; PUBMED: 18238951] ">Cazzola 2008</a>). </p> <p>None of the trials reported FEV<sub>1</sub>/FVC ratio, so these data are not included so far in this review. </p> </section> </section> <section id="CD009769-sec-0073"> <h5 class="title">Mortality</h5> <p>Information was insufficient to calculate HRs for all‐cause or respiratory mortality; this method is preferred to the use of odds ratios (<a href="./references#CD009769-bbs2-0041" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>, Chapter 9.2.6). Therefore, we had to use odds ratios. </p> <section id="CD009769-sec-0074"> <h6 class="title">Beclometasone versus placebo</h6> <p>No evidence suggests that all‐cause mortality is altered further by BDP compared with placebo; <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> (n = 194) showed a non‐significant difference (Peto OR 0.94, 95% CI 0.26 to 3.34, P = 0.92). </p> <p>No evidence indicates that respiratory mortality was altered further by BDP compared with placebo. <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> (n = 194) reported a non‐significant Peto OR of 7.03 (95% CI 0.44 to 113.35, P = 0.17; <a href="./references#CD009769-fig-0007" title="">Analysis 1.3</a>). </p> <p><a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> did not document any mortality data. </p> </section> <section id="CD009769-sec-0075"> <h6 class="title">Beclometasone/LABA versus LABA</h6> <p>No evidence suggests that all‐cause mortality is altered further by BDP/FF compared with FF, with <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 474) showing a non‐significant Peto OR of 7.48 (95% CI 0.47 to 120.00, P = 0.16). </p> <p><a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> reported zero events of respiratory mortality in either treatment arm; odds ratios cannot be calculated for zero events. </p> </section> </section> <section id="CD009769-sec-0076"> <h5 class="title">Pneumonia</h5> <section id="CD009769-sec-0077"> <h6 class="title">Beclometasone versus placebo</h6> <p>None of the mono‐inhaler trials reported pneumonia events.</p> </section> <section id="CD009769-sec-0078"> <h6 class="title">Beclometasone/LABA versus LABA</h6> <p>Based on the assumption that the absolute values for self‐reported pneumonias reported in <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 474) pertained to different participants each time, we analysed pneumonia as dichotomous odds ratios using the Peto method. No evidence was found of any difference between BDP/LABA and LABA in terms of the risk of pneumonia (Peto OR 3.88, 95% CI 0.78 to 19.39, P = 0.10). </p> </section> </section> </section> <section id="CD009769-sec-0079"> <h4 class="title">Secondary outcomes</h4> <section id="CD009769-sec-0080"> <h5 class="title">Exercise capacity</h5> <p>Only <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 465) included the six‐minute walking test in its outcomes; investigators reported no evidence of any difference between BDP/LABA and LABA (MD 6.00 metres, 95% CI ‐8.92 to 20.92, P = 0.43). </p> </section> <section id="CD009769-sec-0081"> <h5 class="title">Number of participants with exacerbations</h5> <p>Only <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 465) reported exacerbations as "number of patients with at least one exacerbation". No evidence was found of any difference between BDP/LABA and LABA (OR 0.96, 95% CI 0.64 to 1.45, P = 0.86). </p> </section> <section id="CD009769-sec-0082"> <h5 class="title">Number of exacerbations</h5> <section id="CD009769-sec-0083"> <h6 class="title">Beclometasone versus placebo</h6> <p>Using the logistic regression analysis rate ratio reported in the paper for steroid courses, <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> (n = 194) provided no evidence of a difference in exacerbations for BDP vs placebo (RR 0.80, 95% CI 0.23 to 2.80, P = 0.73). For exacerbations, the study states the numbers of steroid courses and antibiotic courses separately. We chose to use the number of oral steroid courses as a more accurate reflection of an exacerbation than the number of antibiotic courses. </p> <p>Data were insufficient to allow meta‐analysis in <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a>, but investigators reported a “non‐significant” lower rate of exacerbations per year in the BDP group (0.36 exacerbations/y (SE 0.09)) than in the placebo (0.57 (SE 0.13)). </p> </section> <section id="CD009769-sec-0084"> <h6 class="title">Beclometasone/LABA versus LABA</h6> <p>When mean rates of exacerbations per year per participant reported in <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 465) were used, no evidence was found of a statistically significant difference for BDP/LABA compared with LABA (RR 0.97, 95% CI 0.69 to 1.37, P = 0.88). </p> </section> </section> <section id="CD009769-sec-0085"> <h5 class="title">Hospitalisations and length</h5> <section id="CD009769-sec-0086"> <h6 class="title">Beclometasone versus placebo</h6> <p>In <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> (n = 194), the number of (presumably all‐cause) hospitalisations was reported in absolute values, but rate ratios could not be calculated without data on the length of study treatment exposure of each arm. </p> <p>For duration of hospital stay, rate ratios could not be calculated, but the authors reported, "After correction for the total number of days of treatment (56,949 in the beclomethasone and 55,149 in the placebo group), this difference was not found to be significant (Z‐score = 0.93, Wilcoxon rank test)." Because data are skewed, they are not meta‐analysable. </p> <p><a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> did not report on hospitalisations. </p> </section> <section id="CD009769-sec-0087"> <h6 class="title">Beclometasone/LABA versus LABA</h6> <p>Hospitalisations that were due to exacerbations were reported in <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 465) both as "patients with at least one exacerbations leading to hospitalisation", with a non‐significant difference (OR 1.67, 85% CI 0.68 to 4.11, P = 0.26), and as "mean rate of exacerbations leading to hospitalisation", with a significantly increased rate ratio for BDP/LABA from 0.040 per year on LABA to 0.074 per year on combination treatment (RR 1.84, 95% CI 1.17 to 2.90, P = 0.008). The study authors performed a post hoc analysis to account for differences in hospitalisation between countries; however, we did not use this analysis (see <a href="#CD009769-sec-0111">Quality of the evidence</a>). </p> </section> </section> <section id="CD009769-sec-0088"> <h5 class="title">Quality of life</h5> <p><a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 465) reported a bigger decrease in SGRQ (a high score is worse) for BDP/LABA, with a mean difference of ‐0.85 (95% CI ‐3.32 to 1.62, P = 0.50). This finding was neither statistically nor clinically significant (i.e. a change of &gt; 4 SGRQ units). </p> </section> <section id="CD009769-sec-0089"> <h5 class="title">Symptoms</h5> <section id="CD009769-sec-0090"> <h6 class="title">Beclometasone versus placebo</h6> <p><a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> used the Fletcher Dyspnoea Scale (<a href="./references#CD009769-bbs2-0036" title="FletcherCM , JonesNL , BurrowsB , NidenAH . American emphysema and British bronchitis: a standardized comparative study. American Review of Respiratory Disease1964;90:1‐13. ">Fletcher 1964</a>) (a high score is worse) and reported no evidence of a difference between BDP and placebo (MD 0.05, 95% CI ‐0.06 to 0.15, P = 0.40). For this calculation, we had to impute the final values in both arms, as only baseline values and an estimate of the yearly difference (with an SE and P value) were reported. </p> <p>The Fletcher Dyspnoea Scale (scale from 1 to 5) is very similar to the now more commonly used modified Medical Research Council dyspnoea questionnaire (scale from 0 to 4) (also used in <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>—see below). </p> <p>Despite small improvements, <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> reported “no significant effect of active treatment on the Baseline Dyspnoea Index over the study period”. </p> </section> <section id="CD009769-sec-0091"> <h6 class="title">Beclometasone/LABA versus LABA</h6> <p><a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 465) used the modified Medical Research Council dyspnoea questionnaire (<a href="./references#CD009769-bbs2-0053" title="MahlerDA , WellsCK . Evaluation of clinical methods for rating dyspnea. Chest1988;93:580‐6. ">Mahler 1988</a>) (a high score is worse). They reported no evidence of a difference between BDP/LABA and LABA (MD ‐0.12, 95% CI ‐0.26 to 0.02, P = 0.08). </p> <p>The Body Mass Index, airflow Obstruction, Dyspnoea and Exercise capacity (BODE) Index (<a href="./references#CD009769-bbs2-0032" title="CelliBR , CoteCG , MarinJM , CasanovaC , Montes de OcaM , MendezRA , et al. The body‐mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New England Journal of Medicine2004;350(10):1005‐12. [PUBMED: www.ncbi.nlm.nih.gov/pubmed/14999112] ">Celli 2004</a>) was also used in <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>. No evidence was found of any difference in the BODE index (MD ‐0.17, 95% CI ‐0.40 to 0.06, P = 0.14). </p> </section> </section> <section id="CD009769-sec-0092"> <h5 class="title">Use of rescue bronchodilator</h5> <p>In <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>, a statistically significantly difference was reported, with participants in the BDP/LABA group self‐reporting more days without rescue bronchodilator compared with the control group (MD 7.05, 95% CI 0.84 to 13.26, P = 0.03). </p> </section> <section id="CD009769-sec-0093"> <h5 class="title">Other adverse events</h5> <section id="CD009769-sec-0094"> <h6 class="title">Beclometasone versus placebo</h6> <p>For oral candidiasis, <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> (n = 194) showed no significant difference (Peto OR 1.41, 95% CI 0.24 to 8.31, P = 0.70). </p> <p>For dysphonia, <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> (n = 194) had a higher odds ratio for BDP than for control; this bordered on statistical significance (Peto OR 7.18, 95% CI 0.99 to 51.78, P = 0.05). </p> <p>Third, for bone fractures, <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> (n = 194) showed no significant difference (Peto OR 7.03, 95% CI 0.44 to 113.35, P = 0.17). </p> <p><a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> makes no mention of other adverse events. </p> </section> <section id="CD009769-sec-0095"> <h6 class="title">Beclometasone/LABA versus LABA</h6> <p>For oral candidiasis, dysphonia and bone fractures, <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 474) had no events in either arm, which means that the OR is mathematically not estimable for any of these outcomes. </p> <p>Events picked up by QTc interval evaluations and Holter cardiac monitoring are reported narratively only as “rare” in the Results section, and as “none” in the Discussion. For serum cortisol levels, changes from baseline were reported narratively as non‐significant in any group (section “Safety Evaluation”). The plasma glucose levels also were not reported in the Calverley study. </p> </section> </section> <section id="CD009769-sec-0096"> <h5 class="title">Withdrawal</h5> <section id="CD009769-sec-0097"> <h6 class="title">Beclometasone versus placebo</h6> <p>For most outcomes, we were not able to use the <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> results in our meta‐analysis because investigators did not perform an intention‐to‐treat analysis. This problem does not have an impact on the number of withdrawals, however, which is based on the number of participants allocated and randomly assigned at the beginning of the study. Hence, for withdrawals only, we were able to combine <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> meta‐analytically with the other beclometasone mono‐inhaler study. </p> <section id="CD009769-sec-0098"> <p><b>All‐cause withdrawal</b></p> <p>For withdrawal due to any reason, combining the two BDP versus placebo studies (<a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a>; <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a>; n = 292) revealed no difference (Peto OR 1.33, 95% CI 0.83 to 2.14, P = 0.23; I<sup>2</sup> = 0%; <a href="./references#CD009769-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD009769-sec-0099"> <p><b>Adverse event withdrawal</b></p> <p>No significant difference was found in the rate of non‐completion due to adverse events for BDP (OR 1.06, 95% CI 0.52 to 2.19, P = 0.87; <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a>; n = 194). </p> </section> <section id="CD009769-sec-0100"> <p><b>Respiratory withdrawal</b></p> <p>Two studies (<a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a>; <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a>; n = 292) had withdrawal also coded as due to "ineffectiveness of treatment". The meta‐analysis showed no significant difference (Peto OR 1.55, 95% CI 0.60 to 4.04, P = 0.36; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD009769-sec-0101"> <h6 class="title">Beclometasone/LABA versus LABA</h6> <section id="CD009769-sec-0102"> <p><b>All‐cause withdrawal</b></p> <p><a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> (n = 474) showed no evidence that BDP/LABA altered the odds of withdrawal for any reason compared with LABA (Peto OR 0.91, 95% CI 0.54 to 1.53, P = 0.72). </p> </section> <section id="CD009769-sec-0103"> <p><b>Adverse event withdrawal</b></p> <p>No evidence was found to show that BDP/LABA altered the rates of non‐completion due to adverse events (Peto OR 1.82, 95% CI 0.63 to 5.25, P = 0.27; <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>; n = 474). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009769-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009769-sec-0104"></div> <section id="CD009769-sec-0105"> <h3 class="title" id="CD009769-sec-0105">Summary of main results</h3> <p>The main results are summarised in two 'Summary of findings' tables: one for beclometasone/LABA versus LABA (<a href="./full#CD009769-tbl-0001">summary of findings Table for the main comparison</a>) and one for beclometasone versus placebo (<a href="./full#CD009769-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD009769-sec-0106"> <h4 class="title">Beclometasone versus placebo</h4> <p>For beclometasone mono‐inhalers compared with placebo, no statistically significance differences were found in lung function, all‐cause mortality, respiratory mortality, number of exacerbations, number of hospitalisations, symptom scores, adverse events, all‐cause withdrawal and adverse event withdrawal. No data were available on pneumonia, quality of life scales or use of rescue bronchodilators. </p> <p>The quality of the evidence was graded as very low for the outcomes of lung function, pneumonia and all‐cause withdrawal, low for the adverse event candidiasis and moderate for the symptom scores (see <a href="./full#CD009769-tbl-0002">summary of findings Table 2</a> for GRADE reasons). </p> <p>Participants were mainly GOLD stage 2 and 3 COPD sufferers (post‐bronchodilator predicted FEV<sub>1</sub> around 49% (± 12%) in <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> (n = 194) and around 43% (± 14%) in <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> (n = 98)) whose condition had been stable for the previous 3 months. They had on average a 39‐pack‐year history, and most were smokers or ex‐smokers; only 21 participants were never‐smokers. </p> <p>Most of these studies were set in outpatient clinics in France; some took place in the UK. </p> </section> <section id="CD009769-sec-0107"> <h4 class="title">Beclometasone/LABA versus LABA</h4> <p>For beclometasone inhalers combined with LABA (e.g. BDP/FF) compared with inhalers with LABA alone, statistically significant improvements were noted in lung function measurements and self‐reported days without rescue inhalers, both of which are clinically insignificant. A statistically significant increase was seen in the rate of exacerbations leading to hospitalisation for the combination inhaler, but this might be a false‐positive result. No statistically significant changes were noted in all‐cause mortality, pneumonia, exercise capacity, number of participants with exacerbations, rate of exacerbations, quality of life scores, symptom scores, all‐cause withdrawal and adverse event withdrawal. No difference was found in respiratory mortality, and no data were available on all‐cause hospitalisations. </p> <p>The quality of this evidence was graded as high for lung function and as moderate for exacerbations and most other outcomes, but as low and very low for pneumonia and mortality, respectively (see <a href="./full#CD009769-tbl-0001">summary of findings Table for the main comparison</a> for GRADE reasons). </p> <p>Participants were stage 3 COPD sufferers (postbronchodilator predicted FEV<sub>1</sub> was around 45% at baseline) who had been stable for 3 months (including the 4‐week run‐in period). They had a minimum pack‐year history of 20 (participant average 36 pack‐years) and two‐thirds were ex‐smokers. </p> <p>This study took place in 8 European countries.</p> </section> </section> <section id="CD009769-sec-0108"> <h3 class="title" id="CD009769-sec-0108">Overall completeness and applicability of evidence</h3> <p>Four randomised controlled trials were identified that were relevant to only one of the arms of the review question: BDP versus placebo (2 studies: <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a>; <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a>) and BDP/LABA versus LABA (1 included study (<a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>) and 1 ongoing study (<a href="./references#CD009769-bbs2-0017" title="SinghD , KampschulteJ ,  WedzichaJA ,  JonesPW ,  CohuetG ,  CorradiM ,  etal . A trial of beclomethasone/formoterol in COPD using EXACT‐PRO to measure exacerbations. European Respiratory Journal2013;41(1):12‐7. [DOI: 10.1183/09031936.00207611; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/22653766] WedzichaWA . BDP/FF versus formoterol fumarate (FF) in patients with severe COPD (lung function and exacerbation rate). http://clinicaltrials.gov/ct2/show/NCT00929851 (accessed 26 June 2013). ">Wedzicha (FORWARD) 2013</a>)). </p> <p>For a complete picture of the effects of inhaled beclometasone, it was important that the BDP versus placebo arm was included. The external applicability of this arm, however, is limited by current international guideline recommendations of using only BDP/LABA inhalers (see <a href="#CD009769-sec-0025">Description of the intervention</a>). </p> <p>After consulting with the Cochrane Airways Group, we chose not to combine these two review arms meta‐analytically for several reasons. </p> <p> <ol id="CD009769-list-0007"> <li> <p>The combination inhalers (BDP/LABA) use extra‐fine particles of BDP, which is not the case with the mono‐inhalers used in the other review arm (Qvar is a mono‐inhaler with extra‐fine particles, but it is not used in studies in this review). Therefore, the doses of beclometasone used in the two arms were not equivalent, with extra‐fine particles being more potent. It is thought that doubling the dose of extra‐fine particles would make the dosing in the two arms roughly equivalent. </p> </li> <li> <p>Between the two arms, only data at the same time point are provided for one outcome (FEV<sub>1</sub> at 1 year). As lung function does not follow a linear relationship of improvement on ICS treatment over time (Figure 2E, <a href="./references#CD009769-bbs2-0073" title="CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. ">TORCH 2007</a>), it is therefore imprudent to combine outcomes from different time points. </p> </li> <li> <p>For all outcomes, we do not know how the addition of formoterol fumarate in the BDP/LABA treatment arms affected the effects of the BDP component compared with the mono‐inhaler BDP in the other review arm. Combination therapy seems to behave better than ICS monotherapy (<a href="./references#CD009769-bbs2-0073" title="CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. ">TORCH 2007</a>), and LABA has been shown to have a beneficial effect on its own (<a href="./references#CD009769-bbs2-0073" title="CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. ">TORCH 2007</a>). </p> </li> <li> <p>In the BDP/LABA versus LABA arm of the review, BDP/LABA contains FF extra‐fine metered dose inhaler particles in the treatment arm <i>(Foster)</i> but FF dry powder metered dose inhaler particles in the comparison arm <i>(Oxis)</i>. Again, this may reflect a different effective treatment dose. </p> </li> </ol> </p> <section id="CD009769-sec-0109"> <h4 class="title">BDP/LABA versus LABA</h4> <p>The included BDP/LABA versus LABA study (<a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>) addressed most of the review’s outcomes, only lacking the outcomes hospitalisation and length of stay, and some of the projected adverse events (candidiasis—very important to patients, osteopoenia measures, tremor, skin bruising and cataracts). However, the study was too short to allow assessment of mortality. Observational studies could be used to assess these questions, but only randomised controlled trials were included in this review. </p> <p>The participants assessed in this arm were mainly stage 3 COPD sufferers, although their conditions were well controlled because of the long run‐in period. </p> <p>The dose of BDP/FF used in this arm was the normal recommended maximum dose (400/24 μg) (<a href="./references#CD009769-bbs2-0038" title="Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.org/. Barcelona: Global Initiative for Chronic Obstructive Lung Disease, Inc., (accessed 12 January 2011). ">GOLD 2010</a>). </p> <p>The formoterol inhaler used as the comparator was delivered in a dry powder inhaler (DPI) device, whereas the formoterol in the BDP/FF arm was delivered through a metered dose inhaler (MDI) device. DPIs and MDIs behave differently in vitro (<a href="./references#CD009769-bbs2-0051" title="LongestPW , TianG , WalengaRL , HindleM . Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways. Pharmaceutical Research2012;29(6):1670‐88. [DOI: 10.1007/s11095‐012‐0691‐y; http://www.ncbi.nlm.nih.gov/pubmed/22290350; PUBMED: 22290350] ">Longest 2012</a>) and may have different effectiveness in a real‐world setting (<a href="./references#CD009769-bbs2-0063" title="PriceD , HaughneyJ , SimsE , AliM , vonZiegenweidtJ , HillyerEV , et al. Effectiveness of inhaler types for real‐world asthma management: retrospective observational study using the GPRD. Journal of Asthma and Allergy2011;4:37‐47. [DOI: 10.2147/JAA.S17709; http://www.ncbi.nlm.nih.gov/pubmed/21698214; PUBMED: 21698214] ">Price 2011</a>), although systematic reviews of RCTs have found no real difference between inhaler types (<a href="./references#CD009769-bbs2-0025" title="BrocklebankD , RamF , WrightJ , BarryP , CatesC , DaviesL , et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technology Assessment2001;5(26):1‐149. [http://www.ncbi.nlm.nih.gov/pubmed/11701099; PUBMED: 11701099] ">Brocklebank 2001a</a>; <a href="./references#CD009769-bbs2-0026" title="BrocklebankD , WrightJ , CatesC . Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. British Medical Journal2001;323(7318):896‐900. [http://www.ncbi.nlm.nih.gov/pubmed/11668133] ">Brocklebank 2001b</a>; <a href="./references#CD009769-bbs2-0034" title="DolovichMB , AhrensRC , HessDR , AndersonP , DhandR , RauJL , et al. American College of Chest Physicians, American College of Asthma, Allergy , Immunology . Device selection and outcomes of aerosol therapy: evidence‐based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest2005;127(1):335‐71. [DOI: 10.1378/chest.127.1.335; http://www.ncbi.nlm.nih.gov/pubmed/15654001; PUBMED: 15654001] ">Dolovich 2005</a>). <a href="./references#CD009769-bbs2-0046" title="KempL , HaughneyJ , BarnesN , SimsE , vonZiegenweidtJ , HillyerEV , et al. Cost‐effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: a real world observational study. ClinicoEconomics and Outcomes Research2010;2:75‐85. [http://www.ncbi.nlm.nih.gov/pubmed/21935316/; PUBMED: 21935316] ">Kemp 2010</a> suggested that the difference between real‐life and RCT findings may be selection bias in RCT participant demographics or the extensive training in inhaler technique received by RCT participants. Furthermore, with all of the evidence cited above, no trials compare DPIs with extra‐fine particle MDIs (such as the one used in the BDP/FF arm of <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>), which provide better drug delivery than normal MDIs (<a href="./references#CD009769-bbs2-0042" title="IvancsóI , BöcskeiR , MüllerV , TamásiL . Extrafine inhaled corticosteroid therapy in the control of asthma. Journal of Asthma and Allergy2013;6:69‐80. [DOI: 10.2147/JAA.S25415; http://www.ncbi.nlm.nih.gov/pubmed/23776339; PUBMED: 23776339] ">Ivancsó 2013</a>). </p> <p>Despite the discussion on whether the dose‐delivery curve is different for the two formoterol drugs used in <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>, the study does enable clinicians to assess whether a BDP/FF MDI is worth considering over available FF DPI drugs in a real‐life clinical setting. Hence this review arm remains externally applicable for the reader. </p> <p>The other BDP/LABA versus LABA study, highlighted for future inclusion (<a href="./references#CD009769-bbs2-0017" title="SinghD , KampschulteJ ,  WedzichaJA ,  JonesPW ,  CohuetG ,  CorradiM ,  etal . A trial of beclomethasone/formoterol in COPD using EXACT‐PRO to measure exacerbations. European Respiratory Journal2013;41(1):12‐7. [DOI: 10.1183/09031936.00207611; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/22653766] WedzichaWA . BDP/FF versus formoterol fumarate (FF) in patients with severe COPD (lung function and exacerbation rate). http://clinicaltrials.gov/ct2/show/NCT00929851 (accessed 26 June 2013). ">Wedzicha (FORWARD) 2013</a>), compares an FF MDI device versus a BDP/FF MDI. This may have been done to avoid the issue of how DPI beta‐agonist doses compare with MDI doses. Some trials indicate a "twofold to threefold greater potency" for DPIs of the same brand compared with MDIs, but other trials suggest that some brands of DPI (e.g. <i>Spiros</i>) could change this relation to approximate equipotency (<a href="./references#CD009769-bbs2-0034" title="DolovichMB , AhrensRC , HessDR , AndersonP , DhandR , RauJL , et al. American College of Chest Physicians, American College of Asthma, Allergy , Immunology . Device selection and outcomes of aerosol therapy: evidence‐based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest2005;127(1):335‐71. [DOI: 10.1378/chest.127.1.335; http://www.ncbi.nlm.nih.gov/pubmed/15654001; PUBMED: 15654001] ">Dolovich 2005</a>). This difference between our two BDP/LABA versus LABA studies in their LABA comparator arms will have to be addressed when the decision is made whether to synthesise these studies in the next update. </p> </section> <section id="CD009769-sec-0110"> <h4 class="title">BDP versus placebo</h4> <p>The BDP versus placebo arm of the review contains older studies and less well‐addressed outcomes. These studies did not report on pneumonia, exercise capacity and quality of life scores. The <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> study additionally did not report on mortality and adverse outcomes. </p> <p>Participants in the <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> study were also mainly stage 3 COPD sufferers, although with a wider normal distribution (the inclusion criterion was &lt; 70% FEV<sub>1</sub>; the baseline characteristics were FEV<sub>1</sub> predicted of 41.4% (SE 16) and 39.7% (SE 16) for placebo and BDP, respectively). Interpretation of the staging of the <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> participants is more complex as was their inclusion criterion (pre‐bronchodilator, likely) of FEV<sub>1</sub> 30% to 60% of predicted. Modern staging, however, is done postbronchodilator. Expert opinion was that prebronchodilation or postbronchodilation status was unlikely to affect the staging significantly, and that therefore we could regard these participants as mainly GOLD stage 3 (30% to 50% predicted), with the remainder (50% to 60%) in GOLD stage 2. </p> <p>The doses used in this arm were relatively high, reaching 1500 μg—more than the then‐recommended maximum of 1000 μg (<a href="./references#CD009769-bbs2-0028" title="British Thoracic Society Standards of Care Committee. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax1997;52(Suppl 5):S1‐8. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1765890/; PMCID: PMC1765890] ">BTS 1997</a>). The inhalers were CFC‐propellant inhalers, unlike the HFA inhalers used now. The dosing relationship of CFC inhalers compared with HFA inhalers is being debated (<a href="./references#CD009769-bbs2-0047" title="KunkaR , AndrewsS , PimazzoniM , CallejasS , ZivianiL , SquassanteL , et al. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respiratory Medicine2000;94(Suppl B):S10‐6. [PUBMED: 10919680 ] ">Kunka 2000</a>; <a href="./references#CD009769-bbs2-0048" title="LeachCL , DavidsonPJ , BoudreauRJ . Improved airway targeting with the CFC‐free HFA–beclomethasone metered‐dose inhaler compared with CFC–beclomethasone. European Respiratory Journal1998;12:1346–53. [DOI: 10.1183/09031936.98.12061346; PUBMED: 9877489] ">Leach 1998</a>). </p> </section> </section> <section id="CD009769-sec-0111"> <h3 class="title" id="CD009769-sec-0111">Quality of the evidence</h3> <p>A Grading of Recommendations Assessment, Development and Evaluation (GRADE) rating has been given to each outcome reported per review question arm, along with an explanation for the grading, in the 'Summary of findings' tables (<a href="./full#CD009769-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009769-tbl-0002">summary of findings Table 2</a>). </p> <p>Overall, the identified body of evidence does not allow a robust conclusion regarding the review’s objectives. Only three studies were included, with a total of 768 participants and with 175 participants not completing the trials. </p> <section id="CD009769-sec-0112"> <h4 class="title">Weir 1999</h4> <p>The <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> study especially suffered a high dropout rate, retaining only 60% of its participants after the full two years. This highlights the difficulty involved in answering the question of steroid effectiveness in COPD. The gold standard comparison for any medication is placebo control. Whereas the <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> control group was being treated with formoterol (which has some beneficial effects in itself), participants in the control group of <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> were taking no medication (except symptomatic relief medication, with a few participants taking theophylline). This is not sustainable in a chronic, progressively worsening condition over a long period of time, and it may explain the high dropout rate (no data were provided on whether the dropout rate was higher in the placebo or the treatment group, but participants who withdrew had "significantly worse lung function"). </p> <p>This was compounded by the lack of ITT analysis in the <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> study, along with a limited description of its methods, leading to a bias assessment that was mainly graded as "unclear". </p> </section> <section id="CD009769-sec-0113"> <h4 class="title">Derenne 1995</h4> <p>The <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> study had some methodological queries that could not be resolved when the remaining co‐authors were contacted because of the age of the study. First, we were not sure whether co‐pharmacy with anticholinergics, beta<sub>2</sub>‐agonists, theophylline, mucolytics and almitrine (a respiratory stimulant) was present throughout the trial. Participants were allowed to take these during the pretrial assessment, but it is not specified whether they were discontinued at the start of the trial. The co‐authors have not been able to contact Derenne since 1999. As for the two co‐authors who were contactable, Professor van Weel said, “… I have to rely totally on my memory for this. And according to me, after the inclusion into the study, everyone was placed on the per protocol trial medication with the per protocol rescue medication” [translated, email 18/2/13], whereas Dr Similowski said, “Unfortunately, I cannot tell you more than what is in the manuscript. Logic has it that the treatments were continued, but I cannot be sure. I do not see any means to get the information. Most sorry” [email 18/2/13]. The table of baseline characteristics mentioned the percentage of participants receiving each concomitant drug under the subheading "Concomitant drugs (continuous use)". It is again unclear whether "continuous use" meant that the listed drugs were included in the table only if the participants had previously been receiving continuous therapy for a while, or whether they were continued throughout the trial. </p> <p>Regarding FEV<sub>1</sub>, the actual values and confidence intervals used in the analysis were obtained through manual measurement of the published figure, as these postbronchodilator values were not numerically reported in the paper, which devotes more description to the now devalued pre‐bronchodilator spirometry measurements. </p> <p>Also, the study itself warns that the post‐BD FEV<sub>1</sub> measurements must be interpreted with caution because of the missing values in the multivariate analysis. Hence, the GRADE quality assessment for this outcome was downgraded. </p> <p>For the exacerbation outcome, <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> used a system of respiratory clinic appointments in screening for exacerbation problems. After participants were seen in the clinic, a decision would be made whether their current respiratory problem needed treatment with antibiotics, steroids or both. This almost walk‐in system might be different from the approach used in other studies, which used retrospective reporting based on hospital notes. </p> <p>Derenne reported a P = 0.34 for the steroid course logistic regression analysis: "RR=0,80 {95%c.i. 0.23‐2.80, P=0.34}". The P value that we calculated, however, when using this RR with CIs, is 0.73, with the z‐value being 0.3450. We suggest that the z value and the P value might accidentally have been substituted in the publication. </p> <p>The study reported a table of adverse events, which included the event “bronchitis”. We were uncertain as to what the term "bronchitis" meant in a trial on COPD, where COPD is commonly conceptualised as a chronic bronchitis. Both our expert and the paper's co‐author T. Similowski (Communication by email, 23/03/13) hypothesised that these were exacerbations, rather than pneumonias. As no information was provided in the paper on the definition of the term "bronchitis", we persisted with using the number of oral steroid courses as a more accurate reflection of exacerbations (this also being our protocol definition of exacerbation). As to our choice of steroid courses as opposed to antibiotic courses to represent exacerbations, the numbers were very similar and did not change the outcome. </p> </section> <section id="CD009769-sec-0114"> <h4 class="title">Calverley 2010</h4> <p>The <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> study was very well described. Funding and conflicts of interest were fully declared. </p> <p>Regarding the inclusion criteria for participants, it is claimed that “GOLD” (Global Initiative for Obstructive Lung Disease) criteria were used. According to the description given in the paper, this is indeed the case, except for the small detail that postbronchodilator measurements, according to GOLD, have to be taken 10 to 15 minutes after administration of a short‐acting beta<sub>2</sub>‐agonist (SABA) like salbutamol. The study used 30 minutes instead <i>for the inclusion criterion</i> . This is not expected to have influenced the actual result measurements, however, because <i>for the study assessments</i>, the study says, “Pulmonary function tests (FEV<sub>1</sub>, FVC, …) were measured according to the American Thoracic Society/European Respiratory Society recommendation (<a href="./references#CD009769-bbs2-0056" title="MillerMR , HankinsonJ , BrusascoV , BurgosF , CasaburiR , CoatesA , et al. Standardisation of spirometry. European Respiratory Journal2005;26(2):319‐38. ">Miller 2005</a>)”. Calverley does not specify whether a SABA or a LABA was used as the bronchodilator for all of the postbronchodilator lung function tests, but if investigators adhered to the ATS/ERS guidelines, they would have performed the study assessments within 10 to 15 minutes of using a SABA, or within 30 minutes of using a LABA (<a href="./references#CD009769-bbs2-0056" title="MillerMR , HankinsonJ , BrusascoV , BurgosF , CasaburiR , CoatesA , et al. Standardisation of spirometry. European Respiratory Journal2005;26(2):319‐38. ">Miller 2005</a>, page 327). </p> <p>For lung function measurements, Calverley repeatedly reports all predose, 3 hours postdose and peak measurements. Expert opinion was that the predose measurement was the most important. This is the “trough” measurement, which shows how well the treatment drug is working in the long term. Indeed, Calverley uses predose measurements in defining the primary aim of the study (under the heading "Sample size"). </p> <p>The other measurement of interest, but to a lesser degree, was the 3 hours postdose result. Expert opinion was that this would be a time frame chosen according to the pharmacodynamics of the treatment drugs to show maximal short‐term response. </p> <p>Expert opinion was to reject the third category, peak measurement, as a measure open to bias. </p> <p>Indeed Calverley confirmed this, saying, “I think there was some concern among the sponsors that the pre‐dose may not be the peak effect hence the other 2 secondary outcomes. ... it has been done in other studies so I did not mind collecting data for comparability assessments” (Personal communication by email, 27/2/13). </p> <p>As this is the only study in the review so far that reported predose, 3 hours postdose and peak measurements, we included in the review only the most important measurement: the predose measurement. Neither <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> nor <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> specifies to this extent which measurements were used for lung function in their studies, but predose measurements were likely used. </p> <p>Please note that the terms "pre<i>dose"</i> and "post<i>dose</i> " describe the timing of lung function measurements in reference to administration of the trial drug on that day, not in reference to whether the measurements were pre‐bronchodilator or post<i>bronchodilator</i>. All lung function measurements in Calverley were postbronchodilator, as they were performed according to ATS/ERS guidelines (same above; <a href="./references#CD009769-bbs2-0056" title="MillerMR , HankinsonJ , BrusascoV , BurgosF , CasaburiR , CoatesA , et al. Standardisation of spirometry. European Respiratory Journal2005;26(2):319‐38. ">Miller 2005</a>), and Calverley confirmed by personal communication (email, 27/2/13) that postbronchodilator measurements were used. </p> <p>Regarding adverse events (QTc interval evaluations, Holter monitoring, serum cortisol, plasma glucose, pneumonia), Calverley notes that their study alone was underpowered to exclude these rare events. A meta‐analysis such as this could clarify this part of the research question; however, except for pneumonia, only the Calverley study in this review reports on these outcomes. </p> <p>The pneumonia statistic (which was noticeably higher for BDP/FF than for FF) was not highlighted in the paper, probably because Calverley, as stated above, said that the study was underpowered for these rare adverse events. However, it is of note that pneumonia is a very important outcome in COPD treatment studies, and there was no discussion on whether the difference between BDP/FF and FF was significant. Instead, the rates were only referred to in the discussion as “similar to that reported in placebo‐controlled trials using budesonide, where no pneumonia signals of concern have been observed over 1 year treatment (<a href="./references#CD009769-bbs2-0070" title="SinDA , TashkinD , ZhangX , RadnerF , SjöbringU , ThorénA , et al. Budesonide and the risk of pneumonia: a meta‐analysis of individual patient data. Lancet2009;374:7129. ">Sin 2009</a>)”, with the actual numbers reported only in the accompanying online suppository of extra information. A further explanation for this lack of emphasis is that the data are described as "pneumonia as reported by patients". </p> <p>As mentioned in <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>'s own discussion, a low rate of exacerbations was noted overall compared with previous studies. <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> cited two possible reasons for this: The closer follow‐up provided by physicians could have pre‐empted exacerbations, especially in East European countries, or selection bias could have led to inclusion of more stable participants because of the requirement for 3 months (2 months before inclusion and 4 weeks during the run‐in period) exacerbation‐free. This latter reason is cited by <a href="./references#CD009769-bbs2-0017" title="SinghD , KampschulteJ ,  WedzichaJA ,  JonesPW ,  CohuetG ,  CorradiM ,  etal . A trial of beclomethasone/formoterol in COPD using EXACT‐PRO to measure exacerbations. European Respiratory Journal2013;41(1):12‐7. [DOI: 10.1183/09031936.00207611; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/22653766] WedzichaWA . BDP/FF versus formoterol fumarate (FF) in patients with severe COPD (lung function and exacerbation rate). http://clinicaltrials.gov/ct2/show/NCT00929851 (accessed 26 June 2013). ">Wedzicha (FORWARD) 2013</a> as one of the reasons why they carried out their study. </p> <p>A statistically significant increased rate ratio was noted for the mean rate of exacerbations leading to hospitalisation. This result may have reflected a type I error (a false‐positive effect). In this case, the study authors controlled for the variable 'country‐specific differences in hospitalisation procedures' by accounting for only length of actual hospital treatment for the exacerbations, not total duration of stay. The results of this post hoc analysis show no statistically significant differences (P = 0.607). Arguments for this result reflecting a type I error include the following. </p> <p> <ul id="CD009769-list-0008"> <li> <p>The third arm of the study, which also contained an ICS (budesonide/formoterol, i.e. BUD/FF), had a rate of hospitalised exacerbations (7) similar to that of the formoterol group (8), not similar to that of the beclometasone/formoterol group (13), as would be expected; </p> </li> <li> <p>The numbers of hospitalised exacerbations are low in all three arms of the study, leading to chance variation; </p> </li> <li> <p>The doses of ICS between the BDP/FF and BUD/FF arms should be roughly equivalent, as demonstrated in a previous trial that provided half the dose of each (<a href="./references#CD009769-bbs2-0062" title="PapiA , PaggiaroPL , NicoliniG , VignolaAM , FabbriLM , Inhaled Combination Asthma Treatment versus SYmbicort (ICAT SY) Study Group. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. European Respiratory Journal2007;29(4):682‐9. [DOI: 10.1183/09031936.00095906; http://www.ncbi.nlm.nih.gov/pubmed/17107988; PUBMED: 17107988] ">Papi 2007</a>); </p> </li> <li> <p>If BDP/FF and BUD/FF doses were not equivalent, the effect would be expected to be seen in the opposite direction, as the more potent ICS (extra‐fine particles in the BDP/FF pMDI inhaler vs the BUD/FF DPI inhaler) usually decreases, not increases, the incidence of exacerbations (<a href="./references#CD009769-bbs2-0079" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3; URL: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002991.pub3/abstract] ">Yang 2012</a>); and </p> </li> <li> <p>For the other exacerbation‐related outcome measures ("patients with at least one exacerbation leading to hospitalisation"; "number of patients with at least one (non‐hospitalised) exacerbation"; "mean rate of (non‐hospitalised) exacerbations"), no statistically significant differences were reported. </p> </li> </ul> </p> <p>Whether BDP/FF increases the risk of severe exacerbations compared with FF only is therefore debatable. For the sake of transparency and in the interest of reducing the risk of post hoc analysis bias, however, we disregarded the post hoc analysis. </p> <p>The outcome self‐reported days without bronchodilator was assessed to be low in GRADE quality. This is because of the wide confidence intervals, the fact that self‐reported days is not the best way of assessing this outcome and because self‐reporting is open to introducing bias. </p> </section> </section> <section id="CD009769-sec-0115"> <h3 class="title" id="CD009769-sec-0115">Potential biases in the review process</h3> <p>To minimise the impact of publication bias and to maximise the reliability of our review, we maximised the effort to obtain grey literature. We contacted authors of abstract‐only publications through any means possible to obtain the unpublished full text and were successful in most cases, including the ultimately included <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> study. However, we still await the promised further details of the <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> analysis and the promised <a href="./references#CD009769-bbs2-0016" title="VengerovB . Effectiveness of long‐term treatment with inhaled corticosteroids in metal workers with COPD. European Respiratory Journal Supplement1998;12(Suppl 28):413S. ">Vengerov 1998</a> full text. </p> <p>Extra to the minimum requirements of analysing the Cochrane Airways Group Specialised Register search results, we searched conference proceeding databases and trial registers, obtained licensing information and contacted manufacturers. </p> <p>As the only BDP versus placebo studies we found were an unpublished study (<a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a>) and a study published only with great difficulty as an extended conference proceeding (<a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a>; revealed on communication with author P.S. Burge by email, 20/12/12; see <a href="#CD009769-sec-0067">Other potential sources of bias</a>), we strongly suspected publication bias for this arm of our review. </p> <p>We therefore even went beyond Cochrane methods in trying to determine the existence of unpublished trials by contacting ethics committees and licensing bodies to ask for clinical trial applications related to beclometasone in COPD. This was of particular importance for any potential studies (such as <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a>) that went unpublished before the advent of trial registers after the turn of the century. This proved a difficult search query for most committees and organisations, who were not able to search very far back into the predigital era. As most of the medications used in medical practice today were licensed before the last decade, we suggest this is a problem for the reliability and transparency of the evidence base for many medicines currently in widespread use, such as beclometasone inhalers. </p> <p>Both data extraction and the risk of bias assessment process were made more objective and accurate by having two people perform them (<a href="./references#CD009769-bbs2-0041" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). Bias assessment involves judgement calls and therefore introduces a layer of subjectivity. This is best reduced by having an additional person assess the paper. Data extraction, then, is prone to error if performed by one person only (<a href="./references#CD009769-bbs2-0029" title="BuscemiN , HartlingL , VandermeerB , TjosvoldL , KlassenTP . Single data extraction generated more errors than double data extraction in systematic reviews. Journal of Clinical Epidemiology2006;59:697‐703. ">Buscemi 2006</a>). </p> <p>No limitations were imposed on language. Therefore, a special effort was made with a Spanish record (<a href="./references#CD009769-bbs2-0043" title="IzquierdoJL . Chronic obstructive lung disease: corticosteroids [Corticoides en la EPOC]. Archivos de Bronconeumologia2003;39(Suppl 3):25‐7. ">Izquierdo 2003</a>), which had to be obtained from the author, translated using Google Translate and screened for relevant articles. This led to the identification of the article <a href="./references#CD009769-bbs2-0015" title="WeirDC , BurgePS . Effects of high dose inhaled beclomethasone dipropionate 750 μg and 1500 μg twice daily and 40 mg oral prednisolone on lung function, symptoms and bronchial hyperresponsiveness in patients with non‐asthmatic airflow obstruction. Thorax1993;48(4):309‐16. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC464423/; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/8511727] ">Weir 1993</a>, which was included in the independent assessment phase. Another example is a Chinese paper (<a href="./references#CD009769-bbs2-0008" title="OuyangR , YinB . Clinical study of inhaled corticosteroid in non‐asthmatic chronic obstructive pulmonary disease. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih1998;21(8):497‐9. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/11360524] ">Ouyang 1998</a>), which had to be translated using Google Translate and with the help of an East Asian acquaintance. It was also excluded only at the assessment stage. Thus we tried to reduce any Anglosphere publication bias. </p> <p>Google Translate is free and immediate and shows alternative translations for each sentence. It was very accurate and adept in construing faithful English sentences. </p> <p>As well as being comprehensive, the search was systematic; each step was fully documented.</p> <p>As a medical student, the primary review author DADC had no conflict of interest in presenting data to achieve significant findings but was concerned only with producing a project that met the highest feasible academic standards, independent of the results. </p> <p>The selection criteria set in the protocol had some limitations. The required minimum number of people or a requirement for acceptable power was not prespecified. Neither did we include any detail regarding run‐in periods or medication or regarding co‐therapy with drugs other than ICS. For instance, in <a href="./references#CD009769-bbs2-0011" title="ThompsonAB , MuellerMB , HeiresAJ , BohlingTL , DaughtonD , YanceySW , et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. American Review of Respiratory Disease1992;146(2):389‐95. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/1489129] ">Thompson 1992</a>, several participants were permitted to continue taking theophylline and beta<sub>2</sub>‐agonists during the trial. The only mention of co‐therapy in the protocol involves a subanalysis of whether theophylline was used. This has now been clarified in <a href="#CD009769-sec-0033">Types of interventions</a>. </p> <p>The search strings improved with time, and therefore the searches lack consistency on two points: becodis* (intended to identify the now discontinued brand name Becodisk, Becodisks or the misspelling Becodisc) was added to all searches after 18/03/12, including the search of guideline.gov and OpenGrey.eu, but not CDSR, TRIP, CAGR, … Second, <i>Fostair</i> , a brand name for BDP/FF, is sometimes spelt as <i>Foster</i>, which came to the review authors’ attention only in May 2012. This alternative spelling should therefore have been included in all the searches. </p> <p>It was not feasible with our resources to do a systematic review based on individual participant data. Hence we have used summary data, but we will reconsider when the <a href="./references#CD009769-bbs2-0017" title="SinghD , KampschulteJ ,  WedzichaJA ,  JonesPW ,  CohuetG ,  CorradiM ,  etal . A trial of beclomethasone/formoterol in COPD using EXACT‐PRO to measure exacerbations. European Respiratory Journal2013;41(1):12‐7. [DOI: 10.1183/09031936.00207611; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/22653766] WedzichaWA . BDP/FF versus formoterol fumarate (FF) in patients with severe COPD (lung function and exacerbation rate). http://clinicaltrials.gov/ct2/show/NCT00929851 (accessed 26 June 2013). ">Wedzicha (FORWARD) 2013</a> study is to be included. Combining this data with data from the <a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a> study would be useful in evaluating our BDP/LABA versus LABA comparison. For BDP versus placebo, however, the <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> data have been lost, and for <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a>, we still await the promised new summary data from the author. </p> </section> <section id="CD009769-sec-0116"> <h3 class="title" id="CD009769-sec-0116">Agreements and disagreements with other studies or reviews</h3> <p>No other systematic reviews are looking specifically at BDP among all ICS in COPD. We therefore compare against existing Cochrane reviews of all inhaled corticosteroids. </p> <section id="CD009769-sec-0117"> <h4 class="title">BDP versus placebo</h4> <p>In a Cochrane review comparing all ICS with placebo, <a href="./references#CD009769-bbs2-0079" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3; URL: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002991.pub3/abstract] ">Yang 2012</a> concludes that "clinicians should balance the potential benefits of inhaled steroids in COPD (reduced rate of exacerbations, reduced rate of decline in quality of life and possibly reduced rate of decline in FEV<sub>1</sub>) against the potential side effects (oropharyngeal candidiasis and hoarseness, and risk of pneumonia)". </p> <p>Similarly, the directions of the changes observed in this review for BDP versus placebo were seen as statistically non‐significant improvements in lung function and rate of exacerbations with statistically non‐significant higher occurrences of adverse events. We encountered a lack of data on pneumonia. </p> <p>These similarities must naturally be interpreted with extreme caution, as our findings were not all statistically significant. However, it is possible that with additional study data (such as the <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> data), our confidence in the effect could increase to statistical significance. </p> <p>The <a href="./references#CD009769-bbs2-0079" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3; URL: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002991.pub3/abstract] ">Yang 2012</a> review includes only the <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> study as part of the aforementioned meta‐analysis (<a href="./references#CD009769-bbs2-0074" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta‐analysis. Thorax1999;54(1):7‐14. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10343624] ">van Grunsven 1999</a>). It includes the summary data of <a href="./references#CD009769-bbs2-0074" title="vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta‐analysis. Thorax1999;54(1):7‐14. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10343624] ">van Grunsven 1999</a> meta‐analytically whenever possible. It also fully includes the <a href="./references#CD009769-bbs2-0003" title="WeirDC , BaleGA , BrightP , BurgePS . A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clinical and Experimental Allergy1999;29(Suppl. 2):125‐8. [DOI: 10.1046/j.1365‐2222.1999.00021.x; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10421835] ">Weir 1999</a> study data, and the review authors reached conclusions in their risk of bias assessment that were different from ours. </p> </section> <section id="CD009769-sec-0118"> <h4 class="title">BDP/LABA versus LABA</h4> <p>In comparison with the Cochrane review on the ICS/LABA combination versus LABA, <a href="./references#CD009769-bbs2-0059" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2; URL: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006829.pub2/abstract] ">Nannini 2012</a> concludes, "Concerns over the analysis and availability of data from the studies bring into question the superiority of ICS/LABA over LABA alone in preventing exacerbations. The effects on hospitalisations were inconsistent and require further exploration. There was moderate quality evidence of an increased risk of pneumonia with ICS/LABA. There was moderate quality evidence that treatments had similar effects on mortality. Quality of life, symptoms score, rescue medication use and FEV<sub>1</sub> improved more on ICS/LABA than on LABA, but the average differences were probably not clinically significant for these outcomes. To an individual patient the increased risk of pneumonia needs to be balanced against the possible reduction in exacerbations". </p> <p>This review similarly concludes that statistically significant changes were found in lung function measurements and (self‐reported) days without rescue bronchodilators, which are unlikely to be clinically significant. We did find a statistically and clinically significant increased rate ratio of exacerbations leading to hospitalisation. We did not report statistically significant differences in our other outcomes, as were reported by the <a href="./references#CD009769-bbs2-0058" title="NanniniLJ , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub3] ">Nannini 2007</a> review, but it is suggested that the direction of the changes is similar. Additional study data, such as data derived from the <a href="./references#CD009769-bbs2-0017" title="SinghD , KampschulteJ ,  WedzichaJA ,  JonesPW ,  CohuetG ,  CorradiM ,  etal . A trial of beclomethasone/formoterol in COPD using EXACT‐PRO to measure exacerbations. European Respiratory Journal2013;41(1):12‐7. [DOI: 10.1183/09031936.00207611; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/22653766] WedzichaWA . BDP/FF versus formoterol fumarate (FF) in patients with severe COPD (lung function and exacerbation rate). http://clinicaltrials.gov/ct2/show/NCT00929851 (accessed 26 June 2013). ">Wedzicha (FORWARD) 2013</a> study, may improve our confidence in answering this question. </p> <p>The <a href="./references#CD009769-bbs2-0059" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2; URL: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006829.pub2/abstract] ">Nannini 2012</a> review does not include our only included study in this arm (<a href="./references#CD009769-bbs2-0001" title="CalverleyPM , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. [DOI: 10.1016/j.rmed.2010.09.008; http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712] ">Calverley 2010</a>). </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009769-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram." data-id="CD009769-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Detailed break‐down of results of the search strategy." data-id="CD009769-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Detailed break‐down of results of the search strategy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about all risk of bias items presented as percentages across all included studies." data-id="CD009769-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about all risk of bias items presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009769-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beclometasone versus placebo, Outcome 1 Change in FEV1." data-id="CD009769-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Beclometasone versus placebo, Outcome 1 Change in FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beclometasone versus placebo, Outcome 2 Mortality (dichotomous Peto method)." data-id="CD009769-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Beclometasone versus placebo, Outcome 2 Mortality (dichotomous Peto method).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beclometasone versus placebo, Outcome 3 Exacerbations: mean rate (rate ratio)." data-id="CD009769-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Beclometasone versus placebo, Outcome 3 Exacerbations: mean rate (rate ratio). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beclometasone versus placebo, Outcome 4 Symptoms: change in dyspnoea scale (Fletcher Scale)." data-id="CD009769-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Beclometasone versus placebo, Outcome 4 Symptoms: change in dyspnoea scale (Fletcher Scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beclometasone versus placebo, Outcome 5 Adverse events." data-id="CD009769-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Beclometasone versus placebo, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beclometasone versus placebo, Outcome 6 Withdrawal." data-id="CD009769-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Beclometasone versus placebo, Outcome 6 Withdrawal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 1 Change in FEV1." data-id="CD009769-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 1 Change in FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 2 Mortality (all‐cause) (dichotomous Peto method)." data-id="CD009769-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 2 Mortality (all‐cause) (dichotomous Peto method). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 3 Pneumonia: participants with at least one (dichotomous Peto odds ratios)." data-id="CD009769-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 3 Pneumonia: participants with at least one (dichotomous Peto odds ratios). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 4 Change in exercise capacity: 6MWT." data-id="CD009769-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 4 Change in exercise capacity: 6MWT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 5 Exacerbations: participants with at least one (dichotomous)." data-id="CD009769-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 5 Exacerbations: participants with at least one (dichotomous). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 6 Exacerbations (hospitalisations): participants with at least one (dichotomous)." data-id="CD009769-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 6 Exacerbations (hospitalisations): participants with at least one (dichotomous). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 7 Exacerbations (hospitalisations): mean rate (rate ratio)." data-id="CD009769-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 7 Exacerbations (hospitalisations): mean rate (rate ratio). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 8 Number of hospitalisations (rate ratio)." data-id="CD009769-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 8 Number of hospitalisations (rate ratio). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 9 Change in Quality of Life: SGRQ." data-id="CD009769-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 9 Change in Quality of Life: SGRQ. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 10 Symptoms: change in dyspnoea scale (modified Medical Research Council questionnaire)." data-id="CD009769-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 10 Symptoms: change in dyspnoea scale (modified Medical Research Council questionnaire). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 11 Symptoms: change in BODE index." data-id="CD009769-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 11 Symptoms: change in BODE index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 12 Use of rescue bronchodilators: self‐reported days without." data-id="CD009769-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 12 Use of rescue bronchodilators: self‐reported days without. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 13 Adverse events." data-id="CD009769-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 13 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009769-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/urn:x-wiley:14651858:media:CD009769:CD009769-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_t/tCD009769-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 14 Withdrawal." data-id="CD009769-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 14 Withdrawal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/media/CDSR/CD009769/image_n/nCD009769-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009769-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beclometasone/LABA compared with LABA for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beclometasone/LABA compared with LABA for COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20<br/> <b>Settings:</b> 76 centres in 8 European countries (Bulgaria, France, Italy, Poland, Russia, Spain, Ukraine, United Kingdom)<br/> <b>Intervention:</b> beclometasone/formoterol<br/> <b>Comparison:</b> formoterol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Formoterol</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Beclometasone/Formoterol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in FEV<sub>1</sub> </b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in FEV<sub>1</sub> in the intervention groups was<br/> <b>0.05 higher</b> <br/> (0 to 0.1 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality (all‐cause) (dichotomous Peto method)</b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 7.48</b> <br/> (0.47 to 120) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>474<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia: participants with at least one (dichotomous Peto odds ratios)</b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> <br/> (3 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 3.88</b> <br/> (0.78 to 19.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>474<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations: participants with at least one (dichotomous)</b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>283 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 1000</b> <br/> (202 to 364) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.96</b> <br/> (0.64 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life: SGRQ</b> <br/> Scale: 0 to 100<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in quality of life: SGRQ in the intervention groups was<br/> <b>0.85 lower</b> <br/> (3.32 lower to 1.62 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: candidiasis</b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>474<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal (all‐cause)</b> <br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (83 to 203) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.91</b> <br/> (0.54 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>474<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Indirectness of outcome. Unlikely to have been powered for this outcome. May be more appropriate to measure this outcome with e.g. a cohort study.<br/> <sup>2</sup>Wide confidence intervals.<br/> <sup>3</sup>Few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beclometasone/LABA compared with LABA for COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009769-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Beclometasone compared with placebo for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beclometasone compared with placebo for COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with stable stage 2 and 3 COPD (mainly FEV<sub>1</sub> 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers<br/> <b>Settings:</b> outpatient lung clinics in France (and additionally, for "withdrawals", the UK)<br/> <b>Intervention:</b> beclometasone<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Beclometasone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in FEV<sub>1</sub> </b> —<b>at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in FEV<sub>1</sub>—at 2 years in the intervention groups was<br/> <b>0.03 higher</b> <br/> (0.25 lower to 0.31 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality (all‐cause) (dichotomous Peto method)</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (14 to 157) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.94</b> <br/> (0.26 to 3.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia: participants with at least one (dichotomous Peto odds ratios)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations: participants with at least one (dichotomous)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptoms: change in dyspnoea scale (Fletcher Scale)</b> <br/> Fletcher dyspnoea scale (1 to 5)<br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean symptoms: Change in dyspnoea scale (Fletcher Scale) in the intervention groups was<br/> <b>0.05 higher</b> <br/> (0.06 lower to 0.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: candidiasis</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> <br/> (5 to 151) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.41</b> <br/> (0.24 to 8.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal (all‐cause)</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>336 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>402 per 1000</b> <br/> (295 to 520) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.33</b> <br/> (0.83 to 2.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The Derenne 1995 study was assessed as at high risk of incomplete outcome data for FEV<sub>1</sub> (see the <a href="./references#CD009769-bbs2-0002" title="DerenneJP . Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine1995;151:A463. vanGrunsvenPM . Chapter 8: Beneficial clinical effects of a two‐year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo‐controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002] ">Derenne 1995</a> 'Risk of bias' table).<br/> <sup>2</sup>Wide confidence intervals (includes null effect).<br/> <sup>3</sup>For the beclometasone versus placebo studies, we strongly suspected publication bias (see section "Potential biases in the review process").<br/> <sup>4</sup>All‐cause mortality is a very objective outcome measure, and no significant difference was noted in participants lost to follow‐up through withdrawal.<br/> <sup>5</sup>Indirectness of outcome, as the Derenne study was unlikely to be powered for comparing this outcome. A cohort study may be more appropriate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Beclometasone compared with placebo for COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/full#CD009769-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009769-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beclometasone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality (dichotomous Peto method) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 All‐cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Respiratory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Exacerbations: mean rate (rate ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Symptoms: change in dyspnoea scale (Fletcher Scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Dysphonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Bone fractures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 All‐cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.83, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.52, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Due to ineffectiveness of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.60, 4.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beclometasone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009769-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Beclometasone/formoterol versus formoterol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality (all‐cause) (dichotomous Peto method) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 All‐cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Respiratory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pneumonia: participants with at least one (dichotomous Peto odds ratios) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change in exercise capacity: 6MWT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Exacerbations: participants with at least one (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Exacerbations (hospitalisations): participants with at least one (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Exacerbations (hospitalisations): mean rate (rate ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of hospitalisations (rate ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in Quality of Life: SGRQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Symptoms: change in dyspnoea scale (modified Medical Research Council questionnaire) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Symptoms: change in BODE index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Use of rescue bronchodilators: self‐reported days without <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Dysphonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Bone fractures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 All‐cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Beclometasone/formoterol versus formoterol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009769.pub2/references#CD009769-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009769.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009769-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009769-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009769-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009769\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009769\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009769\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009769\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009769\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009769.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009769.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009769.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009769.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009769.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729032459"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009769.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729032463"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009769.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed2fe39d0f56f',t:'MTc0MDcyOTAzMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 